Product	EMA	FDA	EN	Other	WHO	Year	Generic	DrugBank ID	ATC	ChEMBL	Indications	Targets	Last Update	
Abemaciclib	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/dr
ugs/DB12001">DB12001</a>	L01EF03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3301610">CHEMBL3301610</a>	Advanced Breast Cancer; Metastatic Breast Cancer	CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA	2024-07-24
Abiraterone	Y	Y	N		Y	2011	Y	<a href="https://go.drugbank.com/drugs/DB05812">DB05812</a>	L02BX03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL254328">CHEMBL254328</a>	Metastatic Castration Resistant Prostate Cancer	CYP17A1; CPB2; AR; YBX1; TP53; PTEN; SRD5A2; APC; SRD5A1; TSPYL1; SRD5A3; DSE	2024-07-25	
Acalabrutinib	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB11703">DB11703</a>	L01EL02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3707348">CHEMBL3707348</a>	Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma	EPHB3; FGR; EPHA8; EPHX2; EEGV1; EN1; ENO2; EFNA1; EPS15; DXO; ERBB4; TP53; CYP3A4; BTK; TEC; EFNB2; MS4A2	2024-07-24	
Aclarubicin	N	N	N	Japan	N			<a href="https://go.drugbank.com/drugs/DB11617">DB11617</a>	L01DB04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL502620">CHEMBL502620</a>		TOP2A; SMN1; CSF2	2024-07-24	
Adagrasib	N	Y	N		N	2022	N	<a href="https://go.drugbank.com/drugs/DB15568">DB15568</a>	L01XX77	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594350">CHEMBL4594350</a>	Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer	KRAS; GPM6B	2024-07-24	
Afatinib	Y	Y	N		Y	2013	N	<a href="https://go.drugbank.com/drugs/DB08916">DB08916</a>	L01EB03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1173655">CHEMBL1173655</a>	Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer	NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO	2024-07-24	
Aflibercept	Y	Y	N		N	2011	N	<a href="https://go.drugbank.com/drugs/DB08885">DB08885</a>	S01LA05; L01XX44	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1742982">CHEMBL1742982</a>	Metastatic Colorectal Cancer (MCRC)	VEGFA; PIGF; VEGFC; VEGFB; PGF	2024-07-24	
Aldesleukin	N	Y	Y		N	1992	N	<a href="https://go.drugbank.com/drugs/DB00041">DB00041</a>	L03AC01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201438">CHEMBL1201438</a>	High Risk Neuroblastoma; Metastatic Melanoma; Metastatic Renal Cell Carcinoma	IL2RA; IL2RB; IL2RG	2024-07-24	
Alectinib	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB11363">DB11363</a>	L01ED03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1738797">CHEMBL1738797</a>	Refractory, metastatic Non small cell lung cancer	RET; ALK; ROS1; EML4; TP53; CYP3A4; IDH2; HBEGF; DRD4; BRAF	2024-07-24	
Alemtuzumab	Y	Y	N		N	2001	N	<a href="https://go.drugbank.com/drugs/DB00087">DB00087</a>	L04AA34	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201587">CHEMBL1201587</a>	B-Cell Chronic Lymphocytic Leukemia; T-Cell Prolymphocytic Leukemia	CD52; TP53; CXCL12	2024-02-07	
Alitretinoin	Y	Y	N		N	1999	N	<a href="https://go.drugbank.com/drugs/DB00523">DB00523</a>	D11AH04; L01XF02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL705">CHEMBL705</a>	AIDS-related Kaposi&#39;s Sarcoma	RARB; RXRA; RARG; SFTPA1; RXRG; HCN2; RARA; RXRB; ERBB2; BCHE; EHMT2; BCHEL3; GCK; CGA; SERPINE1; CCR2; CD34; BCHEL1; P2RY2; CETP; VDR	2024-07-24	
Alpelisib	Y	Y	N		N	2019	N	<a href="https://go.drugbank.com/drugs/DB12015">DB12015</a>	L01EM03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2396661">CHEMBL2396661</a>	Advanced Metastatic Breast Cancer	F5; PIK3CB; PIK3CG; BRAF; SGK1; CDK4; PIK3CA; PIK3CD; PIK3R2; PIK3C2A; ERBB2; ESR1; FGFR2; PIK3R1; PI4KA; PIK3R4; F7R; MAP2K1; ESR2; PTEN; FGFR3; PIK3C2B; TP53; PIK3R5; PIK3R6; PIK3R3; FGFR1; PIK3C2G; F7; NRAS; MTOR; ARID1A; PIK3C3; RB1; HRAS	2024-07-24	
Altretamine	N	N	Y		N	1990	N	<a href="https://go.drugbank.com/drugs/DB00488">DB00488</a>	L01XX03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1455">CHEMBL1455</a>	Ovarian Cancer; Ovarian Cancer Stage III	CYP1A2	2024-02-07	
Aminolevulinic Acid	Y	Y	N		N	1999	N	<a href="https://go.drugbank.com/drugs/DB00855">DB00855</a>	L01XD04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL601">CHEMBL601</a>	Basal Cell Carcinoma (BCC); Squamous Cell Carcinoma (SCC)	BCL2	2024-02-07	
Amivantamab	Y	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB16695">DB16695</a>	L01FX18	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297774">CHEMBL4297774</a>	Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer	DRD4; DXO	2024-07-24	
Amrubicin	N	N	N	Japan	N	2002		<a href="https://go.drugbank.com/drugs/DB06263">DB06263</a>	L01DB10	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1186894">CHEMBL1186894</a>		TOP2A	2024-02-07	
Amsacrine	N	N	N		N	1987	N	<a href="https://go.drugbank.com/drugs/DB00276">DB00276</a>	L01XX01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL43">CHEMBL43</a>	Leukemia, Acute; Refractory Leukemia	TOP2A; CYP2C9; TOP2B; CBX1; CYP3A4; EHMT2; ATXN2; CYP2C19; HSD17B10; MTOR; CYP2D6; ATAD5; BTF3P11; DRD1; CYP1A2	2024-07-24	
Anastrozole	N	Y	Y		Y	1995	Y	<a href="https://go.drugbank.com/drugs/DB01217">DB01217</a>	L02BG03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1399">CHEMBL1399</a>	Advanced Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer; Invasive, early Breast Cancer	ESR1; IGF2; PGR; CYP19A1; TUBB1; DLG2; MAP4K4; CLDN11; CSMD1; ERBB2; ZNF613; CYP1B1; CPD	2024-07-24	
Apalutamide	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB11901">DB11901</a>	L02BB05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3183409">CHEMBL3183409</a>	Nonmetastatic Prostate Cancer	AR; BEVI	2024-07-24	
Arsenic Trioxide	Y	Y	N		Y	2018	Y	<a href="https://go.drugbank.com/drugs/DB01169">DB01169</a>	L01XX27	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200978">CHEMBL1200978</a>	Refractory Acute Promyelocytic Leukemia	RARA; SMO; IL6; BIRC5; BDNF; CCND1; TXNRD1; FGFR1; MYCN; SERPINE1; IKBKB; HSPA4; PML; JUN; FLT3; MAPK3; EPO; TERT; FAS; GSTO1; CDKN1A; DNMT1; MT1A; MAPK10; TXNRD2; MAPK1	2024-07-25	
Asciminib	Y	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB12597">DB12597</a>	L01EA06	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4208229">CHEMBL4208229</a>	Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	ABL1; BCR	2024-07-24	
Asparaginase	Y	Y	N		Y	1994	N	<a href="https://go.drugbank.com/drugs/DB00023">DB00023</a>	L01XX02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108989">CHEMBL2108989</a>	Acute Lymphoblastic Leukaemias (ALL)	ASNS; PYGL; MYBBP1A; PNPLA3; MTHFR; LPL; MIR4268; GATA3; ATF5; HLA-DRB1; GRIA1; MIR3117; TYMSOS; ETV6; CPA2; NFATC2; TYMS; SOD2	2024-07-24	
Atezolizumab	Y	Y	N		N	2016	N	<a href="https://go.drugbank.com/drugs/DB11595">DB11595</a>	L01FF05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3707227">CHEMBL3707227</a>	Metastatic Non-Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Triple Negative Breast Cancer (TNBC); Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma	CD274	2024-07-24	
Avapritinib	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB15233">DB15233</a>	L01EX18	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4204794">CHEMBL4204794</a>	Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor	KIT; PDGFRA; FLT3; DPT; CBL	2024-07-24	
Avelumab	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB11945">DB11945</a>	L01FF04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3833373">CHEMBL3833373</a>	Locally advanced disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC); Locally advanced disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC); Metastatic Merkel Cell Carcinoma (MCC); Metastatic disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC); Metastatic disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC)	CD274; PMS2; MSH2; MSH6; MLH1; STK11; ATM	2024-07-24	
Axicabtagene Ciloleucel	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB13915">DB13915</a>	L01XX70	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989989">CHEMBL3989989</a>	Refractory Diffuse large B-cell lymphoma NOS; Refractory High grade B-cell lymphoma Burkitt-like lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma; Relapsed Diffuse large B-cell lymphoma NOS; Relapsed High grade B-cell lymphoma Burkitt-like lymphoma; Relapsed Primary Mediastinal Large B-Cell Lymphoma	CD19	2024-02-07	
Axitinib	Y	Y	N		N	2012	N	<a href="https://go.drugbank.com/drugs/DB06626">DB06626</a>	L01EK01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1289926">CHEMBL1289926</a>	Advanced Thyroid cancer	KDR; ABCG2; YES1; FLT1; UGT1A9; UGT1A10; DRD2; PDGFRB; PDGFRA; TP53; VHL; ABL1; FABP5; KIT; CD274; PDGFB; HIF1A; UGT1A7; UGT1A8; BRAF; OR2B11; FLT4	2024-07-24	
Azacitidine	Y	Y	N		N	2004	Y	<a href="https://go.drugbank.com/drugs/DB00928">DB00928</a>	L01BC07	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1489">CHEMBL1489</a>	Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia	NRAS; DNMT1; TG; MTHFR; ALDH1A1; GMNN; NFE2L2; IDH1; SMAD3; XRCC1; KRAS; TAGLN; FLT3; ATAD5; AFP; GGT1; MYC; ABL1; CDA; MGMT; TP53; AR; IDH2; NR3C1; THPO; LIF; HTT; PLAU; PTPN11; DNMT3A; TYMS; CBL; HBB; GSTP1; CD247; RORC; TRIT1; GATA2; TET2; IL11	2024-07-25	
BCG Vaccine	Y	Y	N		Y		N	<a href="https://go.drugbank.com/drugs/DB12768">DB12768</a>	L03AX03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108905">CHEMBL2108905</a>	Non-Invasive Bladder Urothelial Carcinoma; Recurrent Superficial Bladder Cancer; Urothelial Carcinoma Recurrent; Carcinoma in situ of urinary bladder	KLK3; IL2; PIK3CB	2024-07-25	
Belantamab Mafodotin	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB15719">DB15719</a>	L01FX15	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4298209">CHEMBL4298209</a>	Relapsed Or Refractory Multiple Myeloma	ECE1; TUBB; TUBB4A; TUBA1B; TUBA3E; TUBA1C; TUBB2A; TNFRSF17; TUBB2B; TUBB8; TUBA3C; TUBB6; TUBB4B; TUBB3; TUBA4A; TUBA1A; TUBB1	2024-07-24	
Belinostat	N	Y	N		N	2014	N	<a href="https://go.drugbank.com/drugs/DB05015">DB05015</a>	L01XH04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL408513">CHEMBL408513</a>	Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified	UGT1A1; HDAC3; HDAC9; HDAC6; HDAC5; HDAC10; HDAC1; FBXW7; HDAC7; GARS1; KMT2A; GAPDHP1; HDAC11; GART; MSTN; GAS1; GDF9; GAS2; GDF2; HDAC4; HDAC8; HDAC2	2024-07-24	
Belotecan	N	N	N	South Korea	N	2003		<a href="https://go.drugbank.com/drugs/DB12459">DB12459</a>	L01CE04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2111084">CHEMBL2111084</a>		TOP1	2024-02-07	
Belzutifan	N	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB15463">DB15463</a>	L01XX74	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4585668">CHEMBL4585668</a>	Advanced Renal Cell Carcinoma	HMGB2	2024-07-24	
Bendamustine	N	Y	Y		Y	2008	Y	<a href="https://go.drugbank.com/drugs/DB06769">DB06769</a>	L01AA09	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL487253">CHEMBL487253</a>	Chronic Lymphocytic Leukaemia (CLL); Follicular Non-Hodgkin&#39;s Lymphoma Refractory; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Waldenstrom&#39;s Macroglobulinemia (WM); Recurrent multiple myeloma; Refractory indolent B cell non-hodgkin lymphoma	ATM; TP53; CD69	2024-07-24	
Bevacizumab	Y	Y	N		Y	2004	N	<a href="https://go.drugbank.com/drugs/DB00112">DB00112</a>	S01LA08; L01FG01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201583">CHEMBL1201583</a>	Cervical Cancer Metastatic; Metastatic Colorectal Cancer (MCRC); Metastatic Non-Squamous Non-Small Cell Lung Cancer; Metastatic Renal Cell Carcinoma; Persistent Cervical Cancer; Recurrent Cervical Cancer; Recurrent Glioblastoma; Stage III epithelial ovarian cancer following initial surgical resection; Stage IV epithelial ovarian cancer following initial surgical resection; Fallopian tube cancer following initial surgical resection; Locally advanced nonsquamous non-small cell lung cancer; Primary peritoneal cancer following initial surgical resection; Recurrent Non-Squamous Non-Small Cell Lung Cancer; Recurrent Platinum-Sensitive Epithelial Ovarian Cancer; Recurrent Platinum-resistant Epithelial Ovarian Cancer; Recurrent platinum drug resistant Fallopian tube cancer; Recurrent platinum drug resistant primary peritoneal cancer; Recurrent platinum sensitive primary peritoneal cancer; Recurrent platinum-sensitive fallopian tube cancer; Unresectable Non-Squamous Non-Small-Cell Lung Cancer	VHL; CCT3; BRAF; VEGFA; NF2; SLC19A1; SHMT1; HSP90AB1; NF1; GC; KRAS; MMP2; EDN1; ARID1A; MGAT4A; HOXC10; KIT; EGFR; CXCL8; TP53; RALBP1; VEGFB; FOXF1; CSPG4; VEGFC; ANXA11; F2R; EML4; CXCR4; GGH; CD274; PDGFRB; PRKCA; MMP9; ALK; CXCR2; HRAS; PIK3CA; THBS2; IDH1	2024-07-24	
Bexarotene	Y	Y	N		N	1999	Y	<a href="https://go.drugbank.com/drugs/DB00307">DB00307</a>	L01XF03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1023">CHEMBL1023</a>	Refractory peripheral cutaneous T-cell lymphoma	NR1I2; OPN1SW; RXRB; RXRG; USP1; HCN2; NR1H3; RXRA; MAPK8; KAT2A; BLM; CCND1	2024-07-24	
Bicalutamide	N	Y	Y		Y	1995	Y	<a href="https://go.drugbank.com/drugs/DB01128">DB01128</a>	L02BB03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL409">CHEMBL409</a>	Stage D2 Prostatic carcinoma	CYP2B6; CFLAR; AR; BAX; VDR; KLK3; CDH1; KMT2D; FST; BEVI	2024-07-25	
Binimetinib	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB11967">DB11967</a>	L01EE03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3187723">CHEMBL3187723</a>	Metastatic Melanoma; Unresectable Melanoma	BRAF; APC; MAP2K1; ATM; HRAS; NRAS; MAP2K7; UGT1A1; NF1; PTEN; PIK3CA; MAP2K3; KRAS; KIT; MAP2K4; NR2F6; JAK2; MAP2K2; MAP2K6; MAP2K5	2024-07-24	
Bleomycin	N	Y	Y		Y	1973	Y	<a href="https://go.drugbank.com/drugs/DB00290">DB00290</a>	L01DC01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL403664">CHEMBL403664</a>	Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin&#39;s Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi&#39;s sarcoma	CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP	2024-07-24	
Blinatumomab	Y	Y	N		N	2014	N	<a href="https://go.drugbank.com/drugs/DB09052">DB09052</a>	L01FX07	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1742992">CHEMBL1742992</a>	Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory; Relapsed B cell precursor Acute lymphoblastic leukemia	CD3E; CD19; KMT2A; BCR; CD3D; ABL1; GLRA2; CD247; GMFB; CD3G	2024-07-24	
Bortezomib	Y	Y	N		Y	2003	Y	<a href="https://go.drugbank.com/drugs/DB00188">DB00188</a>	L01XG01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL325041">CHEMBL325041</a>	Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM)	PSMB11; PSMB4; PSMB10; PSMC3; HSPB2; AR; BDNF; PSMC2; PSMA7; PSMD4; PSMD2; PSMD7; PSMA4; B2M; PSME2; PSMB1; PSMC5; PSMD12; PSMA6; PSMB5; PSMA2; HSPA4; PSMD1; PMAIP1; PIK3CA; PSMB2; PSME1; BCL2L2; PSMD9; PSMD14; PSMA5; PSMC1P1; PSMB6; PSMA1; ADRM1; PSME4; PSMC6; PSMD11; PLG; PSMD8; PSMB8; PSMB3; NFE2L2; PSMB9; PSMB7; F12; PSMC1; FGFR3; FLT3; PSMD6; PSMC4; NFKB1; E2F1; PRSS2; PSME2P2; CCND1; PSMD13; PSMF1; CAPN1; DDIT3; FRA6F; PSME3; F2; PSMD10P1; PSMA8; PSMD5; BCL2; PSMD4P1; PSMC3IP; PRSS3; PSMD10; TP53; PRB2; PSMD10P3; CTSB; PIK3CG; PSMA3; PIPSL; PSMD10P2; GATA2; CTSL; PRSS1; SEM1; PLAT; XIAP; PSMD3	2024-07-25	
Bosutinib	Y	Y	N		N	2010	N	<a href="https://go.drugbank.com/drugs/DB06616">DB06616</a>	L01EA04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL288441">CHEMBL288441</a>	Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia	EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1	2024-07-24	
Brentuximab vedotin	Y	Y	N		N	2011	N	<a href="https://go.drugbank.com/drugs/DB08870">DB08870</a>	L01FX05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1742994">CHEMBL1742994</a>	B-large cell anaplastic Lymphoma (Kiel Classification) refractory; Refractory Hodgkin Lymphoma; Post-autologous hematopoietic stem cell transplantation Hodgkin lymphoma	TNFRSF8; ALK; TUBA1C; TUBB4B; TUBB3; TUBA3C; TUBB2A; TUBA1A; TUBB8; TUBB2B; TUBA3E; TUBA4A; E4F1; TUBB; TUBA1B; TUBB4A; TUBB1; TUBB6	2024-07-24	
Brexucabtagene Autoleucel	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB15699">DB15699</a>	L01XL06	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594618">CHEMBL4594618</a>	Refractory Mantle Cell Lymphoma; Relapsed Mantle Cell Lymphoma	CD19	2024-02-07	
Brigatinib	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB12267">DB12267</a>	L01ED04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545311">CHEMBL3545311</a>	Metastatic Non-Small Cell Lung Cancer	ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1	2024-07-24	
Buserelin	N	N	Y		N	2017	N	<a href="https://go.drugbank.com/drugs/DB06719">DB06719</a>	L02AE01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2110824">CHEMBL2110824</a>	Stage D2 Prostatic carcinoma	GNRHR; IGFBP1	2024-02-07	
Busulfan	Y	Y	N		N	1954	Y	<a href="https://go.drugbank.com/drugs/DB01008">DB01008</a>	L01AB01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL820">CHEMBL820</a>	Essential Thrombocythemia (ET); Polycythemia Vera (PV); Chronic Chronic myelogenous leukemia	GSTA1; ADK; ABL1; CYP2C19; ABCC3; MTHFR; THPO; ITGAL; BCR; CYP1A2; GALC; GSTM1; CYP2B6; G6PD; CYP2D6; CYP3A4; GSTP1; CYP2C9; SHBG	2024-07-25	
Cabazitaxel	Y	Y	N		N	2010	N	<a href="https://go.drugbank.com/drugs/DB06772">DB06772</a>	L01CD04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201748">CHEMBL1201748</a>	Refractory, metastatic hormone-refractory Prostate cancer	TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5	2024-07-24	
Cabozantinib	Y	Y	N		N	2012	N	<a href="https://go.drugbank.com/drugs/DB08875">DB08875</a>	L01EX07	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105717">CHEMBL2105717</a>	Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer	MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET	2024-07-24	
Calaspargase Pegol	N	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB14730">DB14730</a>		<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108728">CHEMBL2108728</a>	Acute Lymphoblastic Leukaemias (ALL)	ASRGL1	2024-02-07	
Capecitabine	Y	Y	N		Y	1998	Y	<a href="https://go.drugbank.com/drugs/DB01101">DB01101</a>	L01BC06	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1773">CHEMBL1773</a>	Duke&#39;s C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma	MSH2; REV3L; BRAF; SLC22A7; CYP1A1; UPB1; DPYD; PHC1; CD274; GCGR; CCDC77; VPS13D; AREG; TENM4; TMEM131L; CES1P1; ABCG2; TYMS; SLC19A1; CES1; ADGRG7; ZMIZ1; ATM; ANK3; ERBB2; CDX2; PTGS2; TP53; NCOA7; TYMSOS; CCDC70; SPRY2; UGT1A1; CD96; CYP19A1; SELE; LMNTD1; MGAT4A; MIR2054; FAT1; PTEN; MAN1A1; SIRPA; SSU72; DLG5; EXO1; MSH6; MLH1; PPARD; NSUN3; PIK3CA; KRAS; PMS2; SMAD7	2024-07-25	
Capivasertib	Y	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB12218">DB12218</a>	L01EX27	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2325741">CHEMBL2325741</a>	Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer	CSTF3; FKBP2; AKT3; AKT2; TP53; ESR1; STK11; PTEN; ERBB2; ESR2; MTOR; CSTP1; PIK3CA; AKT1	2024-07-24	
Capmatinib	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB11791">DB11791</a>	L01EX17	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3188267">CHEMBL3188267</a>	Metastatic Non-Small Cell Lung Cancer	DRD4; MET; PTEN	2024-07-24	
Carboplatin	N	Y	Y		Y	1989	Y	<a href="https://go.drugbank.com/drugs/DB00958">DB00958</a>	L01XA02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1351">CHEMBL1351</a>	Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin&#39;s lymphoma	MUCL3; BIRC5; SCN10A; XRCC1; EGFR; TNF; ADAMTSL4-AS1; ERCC1; BCL2; GCLC; DDX53; PIK3CA; DOCK8; MTHFR; MSH2; MSH6; CD274; RAF1; KRAS; BRCA2; NRG3; HCP5; SLCO1B3; OR4D6; SLC31A1; NR1I2; ERCC2; GSR; ETS2; FGFR1; MLH1; CYP3A5; C6orf15; ATP7A; DSCAM; PPP1R18; ERBB3; TP53; VEGFA; PRRC2A; TRIM5; HLA-C; ATAT1; BRCA1; ALK; EIF4E2; TP73; UGT1A1; PSORS1C1; GSTT1; ATP7B; TIGD1; NF2; GSTP1; POLK; NRAS; MAD1L1; MAP3K1; MSH5; ROS1; MAPT; RNF8; KAT2A; RRM1; PTEN; XYLT2; KEAP1; GPX5; CDSN; HSD17B10; FNTB; NRG1; ALDH1A1; ACSS2; VDR; SLC19A1; ALDH3A1; CDK2; ASS1; SERPINA5; APEX1; CDKN1A; USP1; LIG3; PMS2; ERBB2; SERPINC1; ABCB1	2024-07-24	
Carfilzomib	Y	Y	N		N	2009	N	<a href="https://go.drugbank.com/drugs/DB08889">DB08889</a>	L01XG02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL451887">CHEMBL451887</a>	Refractory Multiple Myeloma; Waldenstrom&#39;s Macroglobulinemia (WM)	PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5	2024-07-24	
Carmofur	N	N	N	Japan	N			<a href="https://go.drugbank.com/drugs/DB09010">DB09010</a>	L01BC04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL460499">CHEMBL460499</a>		CYP3A4	2024-02-07	
Carmustine	Y	Y	N		N	1977	Y	<a href="https://go.drugbank.com/drugs/DB00262">DB00262</a>	L01AD01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL513">CHEMBL513</a>	Astrocytomas; Brain Stem Gliomas; Ependymomas; Glioblastomas; Medulloblastomas; Mycosis Fungoides (MF); Recurrent Glioblastoma Multiforme; Refractory Hodgkin Lymphoma; Refractory Multiple Myeloma; Tumors Metastatic to Brain; High grade newly diagnosed Glioma; Refractory Non-Hodgkin&#39;s lymphoma	MGMT; ALDH1A1; GSR; CYP2C19; CYP2D6; CYP2C9; PLAU; CYP1A2; G6PD; E2F1; CYP3A4	2024-07-25	
Cemiplimab	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB14707">DB14707</a>	L01FF06	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297723">CHEMBL4297723</a>	Metastatic cutaneous squamous cell carcinoma; Locally advanced cutaneous squamous cell carcinoma, and not a candidate for curative surgery or curative radiation	PDCD1; CD274; EGFR; GM2A; ALK; CDK12; ROS1	2024-07-24	
Ceritinib	Y	Y	N		N	2014	N	<a href="https://go.drugbank.com/drugs/DB09063">DB09063</a>	L01ED02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2403108">CHEMBL2403108</a>	Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer	ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR	2024-07-24	
Cetuximab	Y	Y	N		N	2004	N	<a href="https://go.drugbank.com/drugs/DB00002">DB00002</a>	L01FE01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201577">CHEMBL1201577</a>	Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN); Metastatic Colorectal Cancer (MCRC); Metastatic Squamous Cell Carcinoma of the Head and Neck; Recurrent Squamous Cell Carcinoma of the Head or Neck; Regionally Advanced Squamous Cell Carcinoma of the Head and Neck	NRAS; TGFA; EGFR; EREG; CTNNB1; KRAS; CXCL8; BRAF; NT5E; BDNF; PIK3CA; EGF; NF2; PTEN; CDKN2A; MGAT4A; BAX; BTC; SMAD4; NRG2; NRG3; ERBB2; HRAS; ERBB3; FCGR3A; VPS37A; AREG; DXO; PTP4A3; MET; HBEGF; TP53; MAP2K1; IDH1; NRG1; GC	2024-07-24	
Chlorambucil	N	Y	Y		Y	1957	N	<a href="https://go.drugbank.com/drugs/DB00291">DB00291</a>	L01AA02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL515">CHEMBL515</a>	Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Non-Hodgkin&#39;s Lymphoma (NHL); Waldenstrom&#39;s Macroglobulinemia (WM); Giant follicular lymphoma	ERBB2; GSTM1; TP53; RORC; FANCC; MGMT; GFER; BAZ2B; NFKB1; CXCL12	2024-07-24	
Ciltacabtagene Autoleucel	Y	Y	N		N	2022	N	<a href="https://go.drugbank.com/drugs/DB16738">DB16738</a>		<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4802263">CHEMBL4802263</a>	Refractory Multiple Myeloma, Relapsed Multiple Myeloma		2024-07-24	
Cisplatin	N	Y	Y		Y	1978	Y	<a href="https://go.drugbank.com/drugs/DB00515">DB00515</a>	L01XA01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2068237">CHEMBL2068237</a>	Advanced Pancreatic Cancer; Breast Cancer; Cervical Cancers; Esophageal Cancers; Head and Neck Carcinoma; Hepatobiliary Cancers; Hepatoblastomas; Malignant Neoplasm of Stomach; Medulloblastomas; Metastatic Melanoma; Multiple Myeloma (MM); Neuroblastomas; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer Metastatic; Pleural Mesotheliomas; Primary Central Nervous System Lymphoma (PCNSL); Recurrent Endometrial Cancer; Refractory Hodgkin Lymphoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Thymic Cancer; Advanced Bladder cancer; Metastatic Anal cancer; Metastatic Endometrial cancer; Metastatic Penile cancer; Metastatic Testicular cancer; Refractory Non-Hodgkin&#39;s lymphoma	CSNK2A3; HEXB; ATM; MLLT3; PPP1R13L; PIK3CA; ERCC4; PLAU; DCBLD1; HMGB1; TPMT; TP53; ERCC1; SYNE3; MECP2; FXN; FGFR1; BAX; ATR; ANPEP; CLCN6; BRCA1; CBX1; BCL2; FANCC; GRP; ERCC6; DFFB; GALNT14; IL6; PRL; GPX5; HPGD; GNAS; TGM2; DDIT3; MGMT; ESR1; MDH2; FASLG; NFE2L2; MPHOSPH8; KDM4E; XIAP; MUTYH; CASP3; CGA; XRCC1; RGS4; TERC; ABCC1; G6PD; CDC25C; GADD45A; ERCC2; FAS; TOP1; KRAS; GSTP1; GSTT1; ATRX; GABPA; GCLM; GCLC; ABCC4; SLC19A1; TYMS; HSD17B10; CYBA; ASS1; LIF; AURKA; ALDH1A1; MTHFD1; FANCA; POLR1G; CD44; MAPT; ALK; ATP7B; EGFR; RB1; SLC22A1; H2AC25; NRAS; APEX1; RECQL; GSTM4; NF2; PPARD; TMEM43; STAT1; OSGEP; GALNT18; DNMT1; BIRC7; MT1H; NR1I2; MAP3K1; RARS1; NHLH1; BRCA2; MDM2; MIR21; EHMT2; IDH1; XRCC3; TP73; SMARCA4; MYCN; CCND1; UBE2I; RAF1; ADH1C; ALOX15; DRAM1; AQP9; HSPA8; ACTL6A; IFNG; E2F1; SEMA6A; KRT20; CDH17; HTR4; MT1F; WFS1; BIRC5; NRG1; RRM1; CHEK1; ABCC5; HSPA4; MSH2; ACSS2; BLMH; CDK12; KAT2A; XRCC5; PTEN; CXCR4; NTRK2; FGFR3; MYC; CD274	2024-07-25	
Cladribine	Y	Y	N		N	1993	Y	<a href="https://go.drugbank.com/drugs/DB00242">DB00242</a>	L04AA40; L01BB04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1619">CHEMBL1619</a>	Chronic Lymphocytic Leukaemia (CLL); Cutaneous T-Cell Lymphoma (CTCL); Hairy Cell Leukemia (HCL); Non-Hodgkin&#39;s Lymphoma (NHL)	DCK; TP53; XIAP; RRM2B; TGFB1; BCL2L2; RRM1; RRM2; CDKN1A; DIABLO; ADA; YES1; IL2RA; NT5C1A; NFE2L2	2024-07-24	
Clofarabine	Y	Y	N		N	2004	Y	<a href="https://go.drugbank.com/drugs/DB00631">DB00631</a>	L01BB06	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1750">CHEMBL1750</a>	Acute Lymphoblastic Leukaemia Recurrent; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myelogenous Leukemia (AML); Refractory Langerhans cell histiocytosis	RRM2; AR; POLA1; POLD2; POLA2; FLT3; POLE2; PRIM1; NIPSNAP2; POLD1; APBB1; GBA1LP; RRM2B; POLD3; POLE3; POLE; PRIM2; POLD4; RRM1	2024-07-24	
Cobimetinib	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB05239">DB05239</a>	L01EE02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2146883">CHEMBL2146883</a>	Metastatic Melanoma; Unresectable Melanoma	BRAF; NRAS; MAP2K2; NR2F6; KRAS; CDKN2A; PIK3CA; MAP2K7; CBL; MAP2K5; MAP2K6; MAP2K4; ERCC2; MAP2K1; NF1; RAF1; MAP2K3; ARAF	2024-07-24	
Copanlisib	N	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB12483">DB12483</a>	L01EM02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3218576">CHEMBL3218576</a>	Relapsed Follicular Lymphoma	PIK3R2; NRAS; PIK3CG; PIK3R4; PIK3R5; PIK3CD; PIK3CB; PIK3CA; PIK3R3; F7; KIT; PIK3C3; PIK3R6; F7R; PIK3C2A; PTEN; PIK3C2G; AURKB; ETFB; F5; PIK3R1; PIK3C2B	2024-07-24	
Crizotinib	Y	Y	N		N	2011	N	<a href="https://go.drugbank.com/drugs/DB08865">DB08865</a>	L01ED01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL601719">CHEMBL601719</a>	Metastatic Non-Small Cell Lung Cancer	ROS1; EML4; DRD4; ALK; NPM1; BRAF; MET; ABCB1; KIT; HBEGF; TP53; ERBB2; PIK3CA; JAK2; NTRK1; PTPN12; ABL1; IGF1R; KEAP1; NTRK2; MDM2; KRAS; NTRK3; AREG; HRAS; EGFR	2024-07-24	
Cyclophosphamide	N	Y	Y		Y	1959	Y	<a href="https://go.drugbank.com/drugs/DB00531">DB00531</a>	L01AA01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL88">CHEMBL88</a>	Acute Lymphoblastic Leukaemias (ALL); Acute Myelocytic Leukemia; Adenocarcinoma of the Ovaries; Breast Cancer; Burkitt&#39;s Lymphoma; Chronic Lymphocytic Leukaemia (CLL); Chronic Myeloid Leukemia (CML); Disseminated Neuroblastoma; Ewing&#39;s Sarcoma; Lung Cancers; Lymphoma, Hodgkins; Multiple Myeloma (MM); Non-Hodgkin&#39;s Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Waldenstrom&#39;s Macroglobulinemia (WM); Advanced Alibert-Bazin syndrome; Histiocytic lymphoma; Metastatic gestational trophoblastic tumor; Mixed-cell type lymphoma; Refractory Small cell lung cancer; Relapsed Wilm&#39;s tumor	EHMT2	2024-07-25	
Cytarabine	Y	Y	N		Y	1969	Y	<a href="https://go.drugbank.com/drugs/DB00987">DB00987</a>	L01BC01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL803">CHEMBL803</a>	Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Leptomeningeal Metastases; Meningeal leukemia; Non-Hodgkin&#39;s Lymphoma (NHL); Blast phase Chronic myelocytic leukemia	ADH1A; IDH2; TP53; CYP3A4; GSTP1; PRIM1; IKZF1; POLA1; HSPA4; KIT; ITGAV; POLD2; GATA3; CCND1; SULT2B1; NQO1; WT1; P2RY12; MSH2; IL1B; EHMT2; TYMSOS; CPT1A; MIR4268; ALK; IGHMBP2; IDH1; CSF2; KMT2A; POLE; NOS3; BIRC5; PRIM2; DOK5; ABCC3; RRM1; CYP2D6; quinone dehydrogenase 2; BMP7; FLT3; TYMS; ATF5; PNPLA3; SLC22A12; NT5C2; POLE2; NRG1; FCGR3A; BRD10; CYP2C9; MIR3117; POLD3; POLA2; SLC29A1; CYP1A2; UGT1A1; VDR; ABCC4; NRAS; RUNX1; RRM2B; POLE3; SLCO1B1; TP73; MED12L; XIAP; FCGR3B; CYP2E1; TPMT; POLD4; NTRK1; CBR3; POLB; MAGEA1; POLD1; NT5C3A; CYP2C19; RRM2; CDA; NCOA3; LINC00251	2024-07-24	
Dabrafenib	Y	Y	N		N	2013	N	<a href="https://go.drugbank.com/drugs/DB08912">DB08912</a>	L01EC02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2028663">CHEMBL2028663</a>	Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric  low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation	NRAS; MAP2K4; MAP2K2; MITF; ALK; HLA-DRB1; HRAS; MAP2K6; PIK3CA; CDKN2A; MAP2K1; G6PD; ATXN1L; EFNA2; AKT1; NF1; RAC1; KRAS; CD274; EML4; MAP2K3; TP53; MAP2K5; MAP2K7; PTEN; BRAF; EZH2	2024-07-24	
Dacarbazine	N	Y	Y		Y	1975	Y	<a href="https://go.drugbank.com/drugs/DB00851">DB00851</a>	L01AX04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL476">CHEMBL476</a>	Advanced Soft Tissue Sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Pheochromocytomas; Advanced Medullary thyroid cancer; Advanced Pancreatic neuroendocrine tumor	ADK; CYP2C19; CYP1A2; CYP2D6; FN1; CYP2C9; POLA2; MGMT; BAX; CYP1A1; CYP3A4; GSTM1; EPM2AIP1; CXCL8; PLAU	2024-07-25	
Dacomitinib	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB11963">DB11963</a>	L01EB07	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2110732">CHEMBL2110732</a>	Metastatic Non-Small Cell Lung Cancer	ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2	2024-07-24	
Dactinomycin	N	Y	N		Y	1964	Y	<a href="https://go.drugbank.com/drugs/DB00970">DB00970</a>	L01DA01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1554">CHEMBL1554</a>	Ewing&#39;s Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms&#39; tumor; Metastatic nonseminomatous Testicular cancer	CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT	2024-07-24	
Daratumumab	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB09331">DB09331</a>	L01FC01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743007">CHEMBL1743007</a>	Multiple Myeloma (MM); Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Relapsed Or Refractory Multiple Myeloma		2024-07-24	
Daratumumab, Hyaluronidase	N	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB09331">DB09331</a>	L01FC01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743007">CHEMBL1743007</a>	Multiple Myeloma (MM); Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Relapsed Or Refractory Multiple Myeloma		2024-07-24	
Darolutamide	Y	Y	N		N	2019	N	<a href="https://go.drugbank.com/drugs/DB12941">DB12941</a>	L02BB06	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297185">CHEMBL4297185</a>	Non-mestatatic castrate-resistant prostate cancer	AR; BEVI	2024-07-24	
Dasatinib	Y	Y	N		Y	2006	Y	<a href="https://go.drugbank.com/drugs/DB01254">DB01254</a>	L01EA02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1421">CHEMBL1421</a>	Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML)	TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3	2024-07-24	
Daunorubicin	N	Y	Y		Y	1979	Y	<a href="https://go.drugbank.com/drugs/DB00694">DB00694</a>	L01DB02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL178">CHEMBL178</a>	Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia	MTHFR; SLC22A7; SLC22A17; TOP2B; KMT2A; MIR4268; IGHMBP2; CYP2J2; MIR3117; ATF5; CPT1A; GPX3; SERPINA6; HTT; POLK; EHMT2; RPSA; AR; WT1; XDH; TOP2A; GATA3; DCK; CDK2; AKR1C3; DOK5; TOP1; THRB; PNPLA3; DNMT3A; TYMSOS; TYMS; ABCC1; BMP7; GSTP1; LINC00251; MAPT; UGT1A1; ABCB1; SLCO1B1; RUNX1; SLC13A3; MAN1B1; APEX1; HDAC4; NOS3; SETD4; HDAC9; GSTA2; IKZF1; HDAC5; ABCG2; HDAC10; HDAC3; APP; CYP1A1; NRP2; NPM1; SLC15A1; ABCA1; SLCO4C1; HDAC1; TPMT; HDAC8; IDH2; ANXA5; AKR1C4; CBR1; HDAC7; KDM4E; CBFB; SLCO6A1; USP1; ABCC9; RECQL; HDAC2; SOD2; AKR7A2; SZRD1; HDAC6; ABCB11; HDAC11; FLT3; GSTM3; COL1A2; FAS; CDA; IDH1; ATP7B; ABCC10; BLM	2024-07-24	
Daunorubicin, Cytarabine Liposome	Y	Y	N		N	2017	Y	<a href="https://go.drugbank.com/drugs/DB00694">DB00694</a>	L01XY01;  L01DB02		Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia		2021-10-28	
Decitabine	Y	Y	N		N	2006	Y	<a href="https://go.drugbank.com/drugs/DB01262">DB01262</a>	L01BC08	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201129">CHEMBL1201129</a>	Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes (MDS)	DNMT3A; CYP27B1; LIF; THBS1; IDH2; KRAS; CDKN2D; TP53; GSTP1; RB1; NR5A1; CDA; GMNN; TGM2; APC; MAGEA1; FLT3; CR2; HLA-E; CCND2; IDH1; CTAG1B; DNMT1; MUC2; IL2RA	2024-07-25	
Decitabine , Cedazuridine	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/Not found in DrugBank">Not found in DrugBank</a>	L01BC58		Acute Myeloid Leukaemia		2023-08-01	
Degarelix	Y	Y	N		N	2008	N	<a href="https://go.drugbank.com/drugs/DB06699">DB06699</a>	L02BX02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL415606">CHEMBL415606</a>	Advanced Prostate Cancer	GNRHR; GNRHR2	2024-07-24	
Denileukin Diftitox	N	Y	N		N	1999	N	<a href="https://go.drugbank.com/drugs/DB00004">DB00004</a>	L01XX29	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201550">CHEMBL1201550</a>	Cutaneous T-Cell Lymphoma (CTCL)	IL2RG; IL2RB; EEF2; IL12RB1; IL12RB2; IL2RA	2024-07-24	
Denosumab	Y	Y	N		N	2010	N	<a href="https://go.drugbank.com/drugs/DB06643">DB06643</a>	M05BX04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1237023">CHEMBL1237023</a>	Giant cell tumor of the bone; Refractory Hypercalcemia of malignancy	TNFSF11; TNFRSF11A; BRAF	2024-07-24	
Dexamethasone	Y	Y	N		Y	1958	Y	<a href="https://go.drugbank.com/drugs/DB01234">DB01234</a>	S03BA01; S02BA06; S01CB01; S01BA01; R01AD03; H02AB02; D10AA03; D07XB05; D07AB19; C05AA09; A01AC02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL384467">CHEMBL384467</a>	Leukemia, Acute; Malignant Lymphomas; Multiple Myeloma (MM); Mycosis Fungoides (MF)	NR3C1; ANXA1; CDK4; CYP2C9; F2RL1; KDR; NRG1; NFE2L2; PTGDR; CHKA; CCL17; RARA; AR; TSC22D3; PZP; DOK5; HSPA8; CDK6; BDM; HTR7; SOAT1; CD86; CARTPT; CRISPLD2; GATA3; SI; CYP2C19; APOB; NR5A1; DPEP1; BMP7; FABP1; RPS19; CYP3A4; CDH17; CHRM3; PYGL; TDO2; CTNNB1; HYAL2; SAG; TYMS; ACTC1; MT1F; GSTP1; TJP1; THRSP; JAK3; S100A10; UBR1; NR1I2; NTRK1; AGTR1; PTH1R; F9; TEAD1; SLC2A4; VEGFA; KRT19; FOLR1; RET; SFTPA1; NPPC; CDK2; SDS; CYP1A2; TGFBR3; BIRC5; VCAM1; GGT1; LIF; IRS2; NR3C2; SERPINE1; IGFBP1; LINC00251; CYP2D6; CHAT; GLS; ALK; UGT1A1; BCL2L11; SMAD3; JUNB; TG; RELA	2024-07-25	
Diethylstilbestrol	N	N	Y		N	1973	N	<a href="https://go.drugbank.com/drugs/DB00255">DB00255</a>	G03CC05; G03CB02; L02AA01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL411">CHEMBL411</a>		BDNF; ESRRB; SLC5A7; GMNN; PTGES3; CYP3A4; AMH; RORC; HRAS; CYP2D6; ESR2; BDKRB2; NPPC; LPO; BDKRB1; CYP1A2; AR; CP; NR1H4; CYP2C19; CYP2C9; NFE2L2; TP53; ERBB2; E2F1; BCYRN1P2; NR1I2; ESRRG; WNT7A; MYC; DNMT1; BCL2; ESR1	2024-07-24	
Dinutuximab	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB09077">DB09077</a>	L01XC16	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3137342">CHEMBL3137342</a>	High Risk Neuroblastoma	MYCN	2024-02-07	
Docetaxel	Y	Y	N		Y	1996	Y	<a href="https://go.drugbank.com/drugs/DB01248">DB01248</a>	L01CD02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL92">CHEMBL92</a>	Esophageal Cancers; Ewing&#39;s Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer	TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3	2024-07-24	
Dostarlimab	Y	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB15627">DB15627</a>	L01FF07	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4298124">CHEMBL4298124</a>	Adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen	POLD1; PDCD1; POLE; MLH1; MSH2; PMS2; MSH6	2024-07-24	
Doxorubicin	N	Y	Y		Y	1974	Y	<a href="https://go.drugbank.com/drugs/DB00997">DB00997</a>	L01DB01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL53463">CHEMBL53463</a>	Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi&#39;s Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom&#39;s Macroglobulinemia (WM); Wilms&#39; tumor; Advanced Thymoma; Advanced uterine sarcoma	ALDH3A1; XIAP; LRP1B; MTHFD1; RARA; BRCA1; PNPLA3; TOP2A; POLK; YWHAG; PAX8; PIK3CB; APEX1; XRCC1; CYP3A4; RXRA; MYOD1; UGT1A1; ABCB11; ZEB1; TET2; CYP2C19; FANCD2; LINC00251; ABCC9; TP53; PIK3CA; AKR7A2; RPSA; TOP2B; MAPK14; SOD2; IL11; HSP90AB1; PIK3CG; WRN; ATM; MGMT; SETD4; CYP2C9; USP1; THRB; RALBP1; RECQL; TPMT; ESR1; SLCO1B1; BDNF; CYP1B1; PLG; EHMT2; IGHMBP2; TGFB1; SRC; MAPK1; CBR1; SDHB; NR1I2; ABCB1; CPT1A; GSTM1; NT5E; SMAD3; HSP90AA1; SLCO6A1; BCL2; COL1A2; BMP7; SERPINA6; AKR1C3; KLC3; SLC22A17; FCGR3B; TAF1; ERCC1; MYB; AR; CAST; NTRK2; ABCC10; NR1H4; CYP1A1; DOK5; GADD45A; XPC; GATA3; BLM; CASP3; ATXN2; ALK; DNMT3A; CYP3A; S100A4; AFP; SLC15A1; MSH2; POLH; GPX3; IDH1; GSR; GBX2; TOP1; NQO1; FASLG; CYP2J2; CYP2D6; BAZ2B; CLCN6; STAT6; ABCA1; PPARD; POLB; SNCA; CCND1; CD274; H2AX; BRAF; CYBA; MDM2; ABCG2; PPM1D; FCGR2A; APAF1; SLC13A3; GALNT14; SLC22A7; SP3; EDN1; MAPT; TGM2; BAX; NFE2L2; CDKN1B; BIRC5; GSTM3; XDH; FLT3; GABPA; ERCC2; CYP1A2; MTR; ABCC5; G6PD; GSTA2; ABCC3; SLCO4C1; FCGR3A; ABCC4; KRT20; KMT2A	2024-07-24	
Doxorubicin Liposome	Y	Y	N		N	1998	Y	<a href="https://go.drugbank.com/drugs/Not found in DrugBank">Not found in DrugBank</a>	L01DB01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL53463">CHEMBL53463</a>	Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi&#39;s Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom&#39;s Macroglobulinemia (WM); Wilms&#39; tumor; Advanced Thymoma; Advanced uterine sarcoma	ALDH3A1; XIAP; LRP1B; MTHFD1; RARA; BRCA1; PNPLA3; TOP2A; POLK; YWHAG; PAX8; PIK3CB; APEX1; XRCC1; CYP3A4; RXRA; MYOD1; UGT1A1; ABCB11; ZEB1; TET2; CYP2C19; FANCD2; LINC00251; ABCC9; TP53; PIK3CA; AKR7A2; RPSA; TOP2B; MAPK14; SOD2; IL11; HSP90AB1; PIK3CG; WRN; ATM; MGMT; SETD4; CYP2C9; USP1; THRB; RALBP1; RECQL; TPMT; ESR1; SLCO1B1; BDNF; CYP1B1; PLG; EHMT2; IGHMBP2; TGFB1; SRC; MAPK1; CBR1; SDHB; NR1I2; ABCB1; CPT1A; GSTM1; NT5E; SMAD3; HSP90AA1; SLCO6A1; BCL2; COL1A2; BMP7; SERPINA6; AKR1C3; KLC3; SLC22A17; FCGR3B; TAF1; ERCC1; MYB; AR; CAST; NTRK2; ABCC10; NR1H4; CYP1A1; DOK5; GADD45A; XPC; GATA3; BLM; CASP3; ATXN2; ALK; DNMT3A; CYP3A; S100A4; AFP; SLC15A1; MSH2; POLH; GPX3; IDH1; GSR; GBX2; TOP1; NQO1; FASLG; CYP2J2; CYP2D6; BAZ2B; CLCN6; STAT6; ABCA1; PPARD; POLB; SNCA; CCND1; CD274; H2AX; BRAF; CYBA; MDM2; ABCG2; PPM1D; FCGR2A; APAF1; SLC13A3; GALNT14; SLC22A7; SP3; EDN1; MAPT; TGM2; BAX; NFE2L2; CDKN1B; BIRC5; GSTM3; XDH; FLT3; GABPA; ERCC2; CYP1A2; MTR; ABCC5; G6PD; GSTA2; ABCC3; SLCO4C1; FCGR3A; ABCC4; KRT20; KMT2A	2024-07-24	
Durvalumab	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB11714">DB11714</a>	L01FF03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3301587">CHEMBL3301587</a>	Unresectable Stage III Non-small Cell Lung Cancer; Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma; Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)	MSH2; IDH1; CD274; PMS2; MLH1; ATM; PDCD1; PBRM1; ALK; MSH6; EGFR	2024-07-24	
Duvelisib	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB11952">DB11952</a>	L01EM04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3039502">CHEMBL3039502</a>	Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed or Refractory Follicular Lymphoma; Refractory, relapsed small lymphocytic lymphoma	F5; TP53; PIK3CD; PIK3CG; F7; PIK3CB; F7R	2024-07-24	
Edotreotide	Y	N	N		N	2019	N	<a href="https://go.drugbank.com/drugs/DB15494">DB15494</a>	V09IX09	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL408350">CHEMBL408350</a>	Neuroendocrine Tumors	FASLG	2024-07-24	
Eflornithine	N	Y	N		Y	2023	N	<a href="https://go.drugbank.com/drugs/DB06243">DB06243</a>	L01XX79	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL830">CHEMBL830</a>	High Risk Neuroblastoma	XIAP; JUN; EHMT2; ODC1; NR5A1; TGM2; KCNA1; MYCN; PRL; ATF2; SMOX	2024-07-24	
Elacestrant	Y	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB06374">DB06374</a>	L02BA04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297509">CHEMBL4297509</a>	Advanced Breast Cancer, Metastatic Breast Cancer	ESR1; ERBB2	2024-07-24	
Elotuzumab	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB06317">DB06317</a>	L01FX08	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743010">CHEMBL1743010</a>	Refractory Multiple Myeloma	GPR27; SLAMF7	2024-07-24	
Elranatamab	Y	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB15395">DB15395</a>	L01FX32	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297809">CHEMBL4297809</a>	Relapsed or Refractory Multiple Myeloma	TNFRSF17; CD3G; CD3D; CD3E	2024-07-24	
Emapalumab	N	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB14724">DB14724</a>	L04AA39	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989977">CHEMBL3989977</a>		IFNG; PRF1; STXBP2; XIAP; SH2D1A; RAB27A; UNC13D; STX11	2024-07-24	
Enasidenib	N	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB13874">DB13874</a>	L01XX59	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989908">CHEMBL3989908</a>	Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML)	IDH2; FLT3; GRB2; IDH1	2024-07-24	
Encorafenib	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB11718">DB11718</a>	L01EC03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3301612">CHEMBL3301612</a>	Metastatic Melanoma; Unresectable Melanoma	KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN	2024-07-24	
Enfortumab Vedotin	Y	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB13007">DB13007</a>	L01FX13	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3301589">CHEMBL3301589</a>	Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer	NECTIN4	2024-02-07	
Entrectinib	Y	Y	N		N	2019	N	<a href="https://go.drugbank.com/drugs/DB11986">DB11986</a>	L01EX14	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1983268">CHEMBL1983268</a>	Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid	NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN	2024-07-24	
Enzalutamide	Y	Y	N		N	2012	N	<a href="https://go.drugbank.com/drugs/DB08899">DB08899</a>	L02BB04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1082407">CHEMBL1082407</a>	Metastatic Castration Resistant Prostate Cancer	BRAF; ATR; ATM; BEVI; CYP17A1; MLH1; PTEN; TP53; CDK12; PIK3CA; APC; BRCA2; AR	2024-07-24	
Epcoritamab	Y	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB16672">DB16672</a>	L01FX27	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650393">CHEMBL4650393</a>	Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL)	CD3D; CD3G; CD3E; MS4A1	2024-07-24	
Epirubicin	N	Y	Y		N	1999	Y	<a href="https://go.drugbank.com/drugs/DB00445">DB00445</a>	L01DB03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL417">CHEMBL417</a>	Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Colorectal Cancers; Hormone Refractory Prostate Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Papillary transitional cell carcinoma of bladder; Recurrent Superficial Bladder Cancer; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Stomach Tumor; Carcinoma in situ of urinary bladder	TUBB2A; HMMR; TYMSOS; FOXO1; PIK3R2; SERPINE1; ABCB1; GCKR; KCNQ1; TOP2A; GNL3; NOS1; SPIDR; TP53; PERP; ERBB2; ABCG2; ABCC2; EPHA6; MDM4; CBR3; INSR; IRS1; BCL2; SLCO1B1; CCNK; BIRC5; MISP; ABCC1; PPP2R5D; FOXP3; RBX1; CHD1; TP53AIP1; SLC28A3; IGF2BP2	2024-07-24	
Erdafitinib	Y	Y	N		N	2019	N	<a href="https://go.drugbank.com/drugs/DB12147">DB12147</a>	L01EN01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545376">CHEMBL3545376</a>	Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma	SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4	2024-07-24	
Eribulin	Y	Y	N		N	2010	Y	<a href="https://go.drugbank.com/drugs/DB08871">DB08871</a>	L01XX41	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1683590">CHEMBL1683590</a>	Metastatic Liposarcoma; Refractory, metastatic Breast cancer; Unresectable Liposarcoma	TERT; TUBB2A; TUBA3E; TUBA1C; ERBB2; TUBB3; TUBB4A; TUBB1; TUBA3C; CYP3A4; ESR1; GCF1; TUBB4B; TUB; ESR2; TUBA1A; TUBB2B; TUBB; PGR; TUBB8; TUBA4A; TUBB6; CD274; TUBA1B; CDK2	2024-07-25	
Erlotinib	Y	Y	N		Y	2004	Y	<a href="https://go.drugbank.com/drugs/DB00530">DB00530</a>	L01EB02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL553">CHEMBL553</a>	Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic	DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1	2024-07-25	
Estramustine	N	Y	Y		N	1981	N	<a href="https://go.drugbank.com/drugs/DB01196">DB01196</a>	L01XX11	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1575">CHEMBL1575</a>	Metastatic Hormone Refractory Prostate Cancer	TDP1; BCL2; BLM; AR; POLK; KAT2A; HEXB; VDR; KLK3; BAX; USP1	2024-07-24	
Etoposide	N	Y	Y		Y	1983	Y	<a href="https://go.drugbank.com/drugs/DB00773">DB00773</a>	L01CB01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL44657">CHEMBL44657</a>	Acute Lymphoblastic Leukaemias (ALL); Acute Myeloid Leukemia (AML); Advanced Hodgkin&#39;s Lymphoma; Ewing&#39;s Sarcoma; Merkel cell cancer; Multiple Myeloma (MM); Neuroblastomas; Neuroendocrine Tumours; Non-Hodgkin&#39;s Lymphoma (NHL); Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Prostate Cancer; Retinoblastoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Wilms&#39; tumor; Locally advanced Thymoma; Metastatic Thymic Cancer; Refractory Sarcoma; Refractory Testicular cancer	GDF15; SLCO1B1; NCOA3; ITGAL; TOP2A; ALK; MAPK1; PLA2G6; MYCN; ABCC1; ABCC3; TP53; AFP; ATM; CHEK1; CYP2D6; FGFR1; SLC2A4; NTRK3; TNFSF13B; HSPB2; KLK3; TYMS; CYP3A4; GSTT1; TOP2B; TBP; GMNN; NR4A1; PGP; SF3B1; DDIT3; SLIT1; NQO1; BLMH; BCL2; IGF2; BAX; TGFB1; CYP2C19; XIAP; GBX2; PLA2G1B; PAPOLA; NCOA1; GSTM1; DYNC2H1; MUC16; BTF3P11; CYP2C9; UGT1A10; GLP1R; TYMSOS; ACTR2; MAPK3; EIF4E; YAP1; CYP1A2; E2F1	2024-07-24	
Everolimus	Y	Y	N		N	2009	Y	<a href="https://go.drugbank.com/drugs/DB01590">DB01590</a>	L04AA18; L01EG02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1908360">CHEMBL1908360</a>	Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom&#39;s Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors	PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET	2024-07-25	
Exemestane	N	Y	Y		N	1999	Y	<a href="https://go.drugbank.com/drugs/DB00990">DB00990</a>	L02BG06	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200374">CHEMBL1200374</a>	Early Breast Cancer; Refractory, advanced Breast cancer	CYP19A1; TCL1A; BGLAP; STK11; ESR1; ESR2; MAP4K4; CYP1B1; PGR; CPD; IGF1R; AKR1C3; NFE2L2; TUBB1; CCDC148; AR; ERBB2	2024-07-24	
Fedratinib	Y	Y	N		N	2019	N	<a href="https://go.drugbank.com/drugs/DB12500">DB12500</a>	L01EJ02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1287853">CHEMBL1287853</a>		JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1	2024-07-24	
Fludarabine	N	Y	Y		Y	1991	Y	<a href="https://go.drugbank.com/drugs/DB01073">DB01073</a>	L01BB05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1568">CHEMBL1568</a>	B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory; Refractory Non-Hodgkin&#39;s lymphoma	MPO; NFE2L2; IKZF1; RRM1; POLA1; POLE3; PRIM2; BAX; POLD2; ADH1A; ATM; RRM2B; PIK3CG; POLA2; SLCO1B1; CYP2E1; POLD3; SLC29A1; SMAD3; POLD4; CXCL12; POLD1; POLE; SULT2B1; POLE2; DCK; SLC22A12; XIAP; RRM2; NIPSNAP2; PRIM1; GBA1LP; ADA; CD40	2024-07-24	
Fluorouracil	N	Y	Y		Y	1962	Y	<a href="https://go.drugbank.com/drugs/DB00544">DB00544</a>	L01BC02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL185">CHEMBL185</a>	Breast Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Rectal Carcinoma; Superficial Basal Cell Carcinoma	OR10AE3P; PERP; BDNF; GCKR; MECP2; RGS5; GNL3; NOS1; TYMS; FPGS; MUC2; DPYD; FOXO1; FGFR4; ABCC4; REV3L; HSPA5; IL11; CYP19A1; KRAS; CSPG4; PIK3R2; CYP3A4; CD274; ERCC1; LGR5; DLG5; OSGEP; TOP2A; NRAS; FAS; TP53AIP1; IGFBP3; MEGF11; XRCC3; CYP3A; KLC1; WNT5B; ATRX; PPP2R5D; ALCAM; EGFR; BRAF; PTEN; KCNQ1; IL6R; TMEM167A; SLC19A1; EXO1; ATM; CYP2E1; PIK3CA; ABCC1; TSHB; HBB; ITGAL; AURKA; DTYMK; CBR1; MSH6; E2F1; PMS2; ABCC2; ABCB1; CHN2; BIRC5; NT5C1A; RALBP1; CYP4X1; TP53; KLC3; ENOSF1; SELE; SCN1A; SMAD4; TYMP; TYMSOS; IGF2BP2; UPB1; RBX1; TWIST1; ABCC5; FGFR2; PTPRC; TPT1; COLEC10; CBR3; CXCL8; CYP2C8; PARD3B; CDKN1A; CYP2C19; PSMB3P1; MSH2; SLC22A16; DKK1; MLH1; MYB; CYP1B1; PDGFRB; MUTYH; IL2RA; CCNK; INSR; ALDH3A1; IRS1; GALNT14; APEX1; BAX; MAP2K1; GNAS; KEAP1; CYP2A6; HMMR; CCND1; CDC25C; NLGN1; MTHFR; ABCG1	2024-07-25	
Fluoxymesterone	N	Y	N		N	1956	Y	<a href="https://go.drugbank.com/drugs/DB01185">DB01185</a>	G03BA01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1445">CHEMBL1445</a>	Inoperable, metastatic Breast cancer	AR; NR3C1; BEVI; PRL	2024-07-24	
Flutamide	N	Y	Y		N	1989	Y	<a href="https://go.drugbank.com/drugs/DB00499">DB00499</a>	L02BB01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL806">CHEMBL806</a>	C Prostatic Carcinoma; Stage B2 Prostatic Carcinoma; Stage D2 Prostatic carcinoma	CYP1A2; RORC; KLK3; AR; EHMT2; NFE2L2; CYP3A4; G6PD; TH; VIP; CYP2C19; CYP2C9; NR1I2; BIRC5; PEBP1; MPO; IL2RA; BEVI; AQP9; CDKN1A	2024-07-24	
Fotemustine	Y	N	N		N			<a href="https://go.drugbank.com/drugs/DB04106">DB04106</a>	L01AD05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL549386">CHEMBL549386</a>	Metastatic Melanoma	MGMT; TXNRD1	2024-02-07	
Fruquintinib	Y	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB11679">DB11679</a>	L01EK04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4303214">CHEMBL4303214</a>	Metastatic Colorectal Cancer	KDR; DRD1; FLT1; DRD2; FLT4; DRD3; KRAS	2024-07-24	
Fulvestrant	Y	Y	N		N	2002	Y	<a href="https://go.drugbank.com/drugs/DB00947">DB00947</a>	L02BA03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1358">CHEMBL1358</a>	Advanced or Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer	TP53; PGR; ESR2; ESR1; EML4; NOS1; EPHX2; ESRRA; FGF2; ERBB2; PIK3CA; PIK3CG; TFPI; BCYRN1P2; PTEN; RB1; CYP1A2; FGFR2; CCNE1; CDK6; XIAP; ALK; ALDH3B1; BDNF	2024-07-25	
Futibatinib	Y	Y	N		N	2022	N	<a href="https://go.drugbank.com/drugs/DB15149">DB15149</a>	L01EN04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3701238">CHEMBL3701238</a>	Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma	NRAS; FGFR3; FGFR4; SLC26A3; DPYSL2; BRAF; DR1; PIK3CA; FGFR1; FGFR2; DPYSL3	2024-07-24	
Gefitinib	Y	Y	N		Y	2003	Y	<a href="https://go.drugbank.com/drugs/DB00317">DB00317</a>	L01EB01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL939">CHEMBL939</a>	Metastatic Non-Small Cell Lung Cancer	PRKD3; EGFR; DXO; HIPK4; MAPK9; TNK2; PLAU; CYP2C9; CHEK2; PHKG2; MET; NUP62; BRAF; FGFR3; BLK; PBK; ERBB3; FRK; IGF1R; MINK1; MAP4K5; ROS1; ERBB4; MAP4K4; LYN; MAPK8; KEAP1; CYP2D6; MAPK14; CRKL; ABCB1; MAPK10; EMP1; SIK2; PRKD2; IRAK4; ALK; CAMK2G; YES1; UHRF1; MAPT; IGF2; PTEN; CAMK2D; SMO; PIM3; ARF1; MAP3K1; SIRT2; HCK; MKNK2; DVL2; LIMK1; PIK3CA; BRSK1; CYP3A5; FLT4; KRAS; ERBB2; LCK; GMNN; CSNK1D; RELA; PIM1; AXL; CEACAM5; SLK; IRAK1	2024-07-24	
Gemcitabine	N	Y	Y		Y	1996	Y	<a href="https://go.drugbank.com/drugs/DB00441">DB00441</a>	L01BC05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL888">CHEMBL888</a>	Advanced Ovarian Cancer; Bladder Transitional Cell Carcinoma Stage IV; Cervical Cancers; Cutaneous T-Cell Lymphoma (CTCL); Head and Neck Carcinoma; Hodgkins Disease (HD); Locally Advanced Pancreatic Adenocarcinoma; Mesothelioma; Metastatic Breast Cancer; Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer (NSCLC), Stage IV; Non-small Cell Lung Cancer Stage IIIA; Small Cell Lung Cancer (SCLC); Stage 4 Pancreatic adenocarcinoma	C6orf15; CYP2C8; NIPSNAP2; ATAT1; AR; WWOX; BRCA2; MDM2; GPX5; SLC29A1; RRM1; POLD1; RAF1; CIP2A; POLE3; TP53; POLD2; POLD4; FKBP5; CHEK1; FANCC; POLD3; CD274; FGFR3; XRCC1; PRIM2; NRAS; POLE2; SERPINC1; POLE; PSORS1C1; TNF; DDX53; NT5C; SERPINA5; RRM2B; BRCA1; PPP1R18; PRB2; CDA; DCP1B; CAMK4; UBASH3B; PRRC2A; MTHFD1; SH2D5; BRAF; PPP1R13L; TNC; OR4D6; DOCK8; PTEN; SLCO1B1; FHL2; IGF2; PPCDC; GBA1LP; ERCC1; RRM2; HCP5; MS4A2; HRAS; ESR2; PIK3CA; SMAD4; POLR1G; MTHFR; ETS2; CDKN2A; CDSN; NT5C1A; SLC29A2; BAZ2B; ACSS2; ALG10; NRG1; MUCL3; HLA-C; WEE1; CDC5L; BTRC; KLC3; XYLT2; MSH5; PRIM1; ALOX5AP; TGM2; CBL; KRAS; TENT4A; ERBB2; POLA2; POLA1	2024-07-24	
Gemtuzumab Ozogamicin	Y	Y	N		N	2000	N	<a href="https://go.drugbank.com/drugs/DB00056">DB00056</a>	L01FX02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201506">CHEMBL1201506</a>	Acute Myeloid Leukemia (AML); Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML)	CYP2E1; SULT2B1; CD33; CHEK1; SLC22A12; SLCO1B1; ADH1A; PML; GAPDHP60; ABCB1	2024-07-24	
Gilteritinib	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB12141">DB12141</a>	L01EX13	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3301622">CHEMBL3301622</a>	Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations	HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B	2024-07-24	
Glasdegib	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB11978">DB11978</a>	L01XJ03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2043437">CHEMBL2043437</a>	Acute Myeloid Leukemia (AML)	SMO; ALOX12; MTOR; FLT3	2024-07-24	
Glofitamab	Y	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB16371">DB16371</a>	L01FX28	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/ CHEMBL4298092"> CHEMBL4298092</a>	Diffuse Large B-Cell Lymphoma (DLBCL), Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	CD3E; MS4A1; CD3G; CD3D	2024-07-24	
Goserelin	N	Y	Y		N	1989	N	<a href="https://go.drugbank.com/drugs/DB00014">DB00014</a>	L02AE03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201247">CHEMBL1201247</a>	Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate	ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR	2024-07-24	
Histamine dihydrochloride	Y	Y	N		N	1939	N	<a href="https://go.drugbank.com/drugs/DB05381">DB05381</a>	L03AX14	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL90">CHEMBL90</a>	Acute Myeloid Leukaemia	AMD1; HRH2; UBE2K; HRH3; GLUD1P3; HRH1; EHMT2; AMELX; SLC29A4; HRH4; GAPDH; USP1; LMNA	2024-07-24	
Histrelin	N	Y	N		N	1991	N	<a href="https://go.drugbank.com/drugs/DB06788">DB06788</a>	L02AE05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201255">CHEMBL1201255</a>	Advanced Prostate Cancer	GNRHR; GNRHR2	2024-02-07	
Hydroxyurea	N	Y	N		N	1967	Y	<a href="https://go.drugbank.com/drugs/DB01005">DB01005</a>	L01XX05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL467">CHEMBL467</a>	Essential Thrombocythemia (ET); Head and Neck Carcinoma; Melanomas; Ovarian Cancer Metastatic; Polycythemia Vera (PV); Chronic, refractory Myeloid Leukemia; Inoperable Ovarian cancer	BLM; PTH; DNMT1; EIF4E; JAK2; TET2; ABL1; MAP3K5; DUSP1; GBA1LP; RRM1; CP; HRAS; ASS1; SIN3A; CYP3A4; NIPSNAP2; KLF4; RRM2B; RRM2; DNTT	2024-07-25	
Ibritumomab Tiuxetan	Y	Y	N		N	2002	N	<a href="https://go.drugbank.com/drugs/DB00078">DB00078</a>	V10XX02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201606">CHEMBL1201606</a>	Follicular Non-Hodgkin&#39;s Lymphoma; Follicular Non-Hodgkin&#39;s Lymphoma Refractory	GATM; MS4A1	2024-07-24	
Ibrutinib	Y	Y	N		N	2013	N	<a href="https://go.drugbank.com/drugs/DB09053">DB09053</a>	L01EL01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1873475">CHEMBL1873475</a>	Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom&#39;s Macroglobulinemia (WM)	CSF3R; BTK; ATM; EGFR; PLCG2; EPHX2; EPHB3; FLT3; MS4A2; MYD88; EFNA1; EEGV1; LYN; ERBB2; EPS15; PIM1; FGR; YES1; MYC; EFNB2; EN1; TEC; FKBP1AP3; TP53; CYP2D6; ERBB4; DXO; ENO2; BMX; EPHA8; SMAD3; BLK; ENUR2	2024-07-24	
Idarubicin	N	Y	Y		N	1990	Y	<a href="https://go.drugbank.com/drugs/DB01177">DB01177</a>	L01DB06	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1117">CHEMBL1117</a>	Acute Myeloid Leukemia (AML)	CBX1; CBR3; CYP2E1; CSF2; POLH; RAPGEF3; FLT3; POLB; SLCO1B1; ETV6; POLI; NQO1; TOP2A; SULT2B1; THRB; ATAD5; FEN1; KCNH2; MPHOSPH8; APEX1; EHMT2; ABCB1; ATXN2; WRN; DRD1; IDH1; MTOR; ERG; PPARD; NT5C3A; HTT; AR; NCF4; USP1; BLM; RECQL; quinone dehydrogenase 2; SLC22A12; DCK; MAPT; BRD10; ADH1A; POLK; RAC2; PLK1; DNMT3A; CYBA; RAPGEF4	2024-07-24	
Idecabtagene Vicleucel	Y	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB16665">DB16665</a>	L01XL07	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4298199">CHEMBL4298199</a>	Refractory Multiple Myeloma, Relapsed Multiple Myeloma	TNFRSF17	2024-02-07	
Idelalisib	Y	Y	N		N	2014	N	<a href="https://go.drugbank.com/drugs/DB09054">DB09054</a>	L01EM01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2216870">CHEMBL2216870</a>	Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma	PIK3CA; PIK3CD; F5; PIK3CB; BRAF; TP53; PTEN; F7; F7R	2024-07-24	
Ifosfamide	N	Y	Y		Y	1988	Y	<a href="https://go.drugbank.com/drugs/DB01181">DB01181</a>	L01AA06	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1024">CHEMBL1024</a>	Cancer, Bladder; Cervical Cancers; Ewing&#39;s Sarcoma; Head and Neck Carcinoma; Lymphoma, Hodgkins; Malignant Neoplasm of Pancreas; Non-Hodgkin&#39;s Lymphoma (NHL); Ovarian Cancer; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Testicular Germ Cell Cancer; Advanced thymic carcinoma	TERC; KLC3; IL6; CYP2A6; DNMT1; GSTP1; TP53; ALDH1A1; CYP2B6; ERCC2; ALK; HSPA4; NR1I2; MGMT	2024-07-24	
Imatinib	Y	Y	N		Y	2001	Y	<a href="https://go.drugbank.com/drugs/DB00619">DB00619</a>	L01EA01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL941">CHEMBL941</a>	Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor	KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT	2024-07-25	
Imiquimod	Y	Y	N		N	1997	Y	<a href="https://go.drugbank.com/drugs/DB00724">DB00724</a>	D06BB10	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1282">CHEMBL1282</a>	Superficial Basal Cell Carcinoma	TLR7; IFNA1; SARDH; GMNN	2024-07-25	
Infigratinib	N	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB11886">DB11886</a>	L01EN03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1852688">CHEMBL1852688</a>	Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas	FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3	2024-07-24	
Inotuzumab Ozogamicin	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB05889">DB05889</a>	L01FB01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108611">CHEMBL2108611</a>	Refractory B-cell precursor acute lymphoblastic leukemia; Relapsed B cell precursor Acute lymphoblastic leukemia	ABL1; GNG4; CD22; BCR	2024-07-24	
Interferon Alfa-2b	Y	Y	N		N	1986	N	<a href="https://go.drugbank.com/drugs/DB00105">DB00105</a>	L03AB05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201558">CHEMBL1201558</a>	Hairy Cell Leukemia (HCL); Kaposi&#39;s sarcoma; Melanoma, Malignant	IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX	2024-07-24	
Iobenguane I-131	N	Y	N		N	1994	N	<a href="https://go.drugbank.com/drugs/DB06704">DB06704</a>	V09IX01; V09IX02; V10XA02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1615779">CHEMBL1615779</a>	Metastatic Pheochromocytoma; Metastatic Neuroblastoma; Primary Neuroblastomas; Primary Pheochromocytomas; Unresectable, locally advanced iobenguane-scan positive Paraganglioma; Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas; Unresectable, metastatic iobenguane-scan positive Paraganglioma; Unresectable, metastatic iobenguane-scan positive Pheochromocytomas	SLC6A2; TH	2024-07-24	
Ipilimumab	Y	Y	N		N	2011	N	<a href="https://go.drugbank.com/drugs/DB06186">DB06186</a>	L01FX04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1789844">CHEMBL1789844</a>	Advanced Renal Cell Carcinoma; Cutaneous Melanoma; Hepatocellular Carcinoma; Metastatic Melanoma; Unresectable Melanoma; Metastatic MSI-H/dMMR colorectal cancer	NRAS; MLH1; TP53; CD274; GLRB; BRAF; ALK; ATM; PTEN; POLE; POLD1; HLA-A; MSH6; MSH2; MDM2; B2M; PMS2; EGFR; CTLA4; PBRM1	2024-07-24	
Irinotecan	N	Y	Y		Y	1996	Y	<a href="https://go.drugbank.com/drugs/DB00762">DB00762</a>	L01CE02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL481">CHEMBL481</a>	Esophageal Cancers; Ewing&#39;s Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma	RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274	2024-07-24	
Irinotecan Liposome	Y	Y	N		N	1996	Y	<a href="https://go.drugbank.com/drugs/DB00762">DB00762</a>	L01XX19	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL481">CHEMBL481</a>	Esophageal Cancers; Ewing&#39;s Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma	RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274	2024-07-24	
Isatuximab	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB14811">DB14811</a>	L01FC02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545131">CHEMBL3545131</a>	Multiple Myeloma (MM)	GMPR	2024-07-24	
Ivosidenib	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB14568">DB14568</a>	L01XX62	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989958">CHEMBL3989958</a>	Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation	IDH2; GPX1P2; IDH1	2024-07-24	
Ixabepilone	N	Y	N		N	2007	N	<a href="https://go.drugbank.com/drugs/DB04845">DB04845</a>	L01DC04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201752">CHEMBL1201752</a>	Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer	ESR1; TUBB; ERBB2; TUBA1C; TUBB2B; TUBA3C; TUBB1; TUBA4A; PGR; TUBB8; TUBA1B; TUBB3; TUBA1A; TUBB2A; ESR2; CYP3A4; TUBA3E; TUBB4B; TUBB4A; TUBB6; TUB; GCF1	2024-07-24	
Ixazomib	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB09570">DB09570</a>	L01XG03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2141296">CHEMBL2141296</a>	Multiple Myeloma (MM)	PSMD6; PSMC3; PSMD13; PSMB4; PSMA4; PSMB7; PSMC6; PSMA3; PSMD3; PSMB2; PSMA1; FRA6F; PSMD2; SEM1; ADRM1; PSMB3; PSMD4; PSMA2; PSMA5; PSMD8; TP53; PSMB10; PSMB5; PSMA7; PSMD14; PSMC1; PSMC5; PSMD12; PSMA8; PSMD1; ALK; EML4; PSMB6; PSMB8; PSMC2; PSMD11; PSMB1; PSMC4; PSMA6; PSMD7; PSMB11; PSMB9	2024-07-24	
Lanreotide	N	Y	Y		N	2007	Y	<a href="https://go.drugbank.com/drugs/DB06791">DB06791</a>	H01CB03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201185">CHEMBL1201185</a>	Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors	SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG	2024-07-25	
Lapatinib	Y	Y	N		N	2007	Y	<a href="https://go.drugbank.com/drugs/DB01259">DB01259</a>	L01EH01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL554">CHEMBL554</a>	Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer	RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1	2024-07-24	
Larotrectinib	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB14723">DB14723</a>	L01EX12	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3889654">CHEMBL3889654</a>	NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive	NTRK1; NTRK3; NTRK2; DRD5P1	2024-07-24	
Lenalidomide	Y	Y	N		Y	2005	Y	<a href="https://go.drugbank.com/drugs/DB00480">DB00480</a>	L04AX04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL848">CHEMBL848</a>	Chronic Lymphocytic Leukemia (CLL) - Refractory; Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); Multiple Myeloma (MM); Myelodysplastic Syndrome; Refractory Diffuse Large B Cell Lymphoma	TNFSF11; RBX1; VEGFC; VEGFB; CUL4A; DDB1; KDR; TP53; TNF; CTNNB1; VEGFA; CRBN; FGF2	2024-07-25	
Lenvatinib	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB09078">DB09078</a>	L01EX08	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1289601">CHEMBL1289601</a>	Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer	DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3	2024-07-24	
Letrozole	N	Y	Y		N	1997	Y	<a href="https://go.drugbank.com/drugs/DB01006">DB01006</a>	L02BG04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1444">CHEMBL1444</a>	Advanced Breast Cancer; Early Breast Cancer; Ovarian Epithelial Cancer; Advanced HR + HER2 - breast cancer; Metastatic HR + HER2 - breast cancer	CDKN2A; CTNNB1; PGR; ESR1; CYP2A6; SFTPA1; PIK3CA; CPD; RB1; CCDC148; CYP1B1; PTEN; MMP2; CYP3A4; KIT; CYP19A1; ERBB2; ZNF613	2024-07-25	
Leuprolide	N	Y	N		N	1985	Y	<a href="https://go.drugbank.com/drugs/DB00007">DB00007</a>	L02AE51; L02AE02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201199">CHEMBL1201199</a>	Advanced Prostate Cancer	CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4	2024-07-24	
Lifileucel	N	Y	N		N	2024	N	<a href="https://go.drugbank.com/drugs/DB17107">DB17107</a>	L01XL11	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4298200">CHEMBL4298200</a>	Unresectable or metastatic melanoma		2024-04-24	
Lisocabtagene Maraleucel	Y	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB16582">DB16582</a>	L01XL08	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297236">CHEMBL4297236</a>	Grade 3b Follicular Lymphoma; High-grade B-cell Lymphoma (HGBCL); Primary mediastinal large B-cell lymphomas; Refractory Diffuse Large B Cell Lymphoma; Refractory Large B-cell Lymphoma; Relapsed Large B-cell Lymphoma; Relapsed, Diffuse Large B-cell Lymphoma,  Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)	CD19	2024-07-24	
Lomustine	N	Y	Y		N	1976	N	<a href="https://go.drugbank.com/drugs/DB01206">DB01206</a>	L01AD02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL514">CHEMBL514</a>	Primary Brain Tumors; Refractory Hodgkin Lymphoma; Tumors Metastatic to Brain	IDH1; MGMT; ADK; EGFR	2024-07-24	
Loncastuximab Tesirine	Y	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB16222">DB16222</a>	L01FX22	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297778">CHEMBL4297778</a>	Refractory Large B-cell Lymphoma, Relapsed Large B-cell Lymphoma	CD19	2024-02-07	
Lorlatinib	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB12130">DB12130</a>	L01ED05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3286830">CHEMBL3286830</a>	Progressive, metastatic Anaplastic lymphoma kinase-positive Metastatic Non-Small Cell Lung Cancer	EML4; ROS1; FGFR1; ENO1; ALK; PIK3CA; NRAS; HRAS; RB1; TP53; BRAF; DTX1; HBEGF	2024-07-24	
Lu 177-Dotatate	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB13985">DB13985</a>	V10XX04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989924">CHEMBL3989924</a>	Gastroenteropancreatic Neuroendocrine Tumors	SSTR1; SSTR5; SSTR3; SSTR2; SSTR4	2024-07-24	
Lurbinectedin	N	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB12674">DB12674</a>	L01XX69	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297516">CHEMBL4297516</a>	Metastatic Small Cell Lung Cancer		2020-09-17	
Lutetium Lu 177 Vipivotide Tetraxetan	Y	Y	N		N	2022	N	<a href="https://go.drugbank.com/drugs/DB16778">DB16778</a>	V10XX05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594406">CHEMBL4594406</a>	Metastatic Castration Resistant Prostate Cancer (CRPC)	FOLH1	2024-02-07	
Margetuximab	N	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB14967">DB14967</a>	L01FD06	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2364649">CHEMBL2364649</a>	HER2-positive Metastatic Breast Cancer	EN1	2024-07-24	
Mechlorethamine	Y	Y	N		N	1949	N	<a href="https://go.drugbank.com/drugs/DB00888">DB00888</a>	L01AA05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL427">CHEMBL427</a>	Carcinoma, Bronchogenic; Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Lymphoma, Diffuse; Mycosis Fungoides (MF); Polycythemia Vera (PV); Stage I Mycosis Fungoides; Malignant effusion	MMP2; GSR; GSTP1; CXCR2; NOS1; BAX; ERBB2; MT-CO1; XRCC1; TSHB; CSF2	2024-07-24	
Medroxyprogesterone	N	Y	Y		N	1959	Y	<a href="https://go.drugbank.com/drugs/DB00603">DB00603</a>	G03DA02; G03AC06; L02AB02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL717">CHEMBL717</a>	Metastatic Renal Cell Carcinoma; Metastatic Endometrial carcinoma	BAX; PGR; VDR; MMP1; CYP1B1; ESR1; CYP3A5	2024-07-24	
Megestrol Acetate	N	Y	Y		N	1971	Y	<a href="https://go.drugbank.com/drugs/DB00351">DB00351</a>	G03DB02; G03AC05; L02AB01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201139">CHEMBL1201139</a>	Advanced Breast Cancer; Advanced Endometrial Cancer	ESR1; ABCB1; AR; PGR; IL2RA; KLK3; NPSR1; IL15; NFE2L2	2024-07-25	
Melphalan	N	Y	Y		Y	1964	Y	<a href="https://go.drugbank.com/drugs/DB01042">DB01042</a>	L01AA03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL852">CHEMBL852</a>	Multiple Myeloma (MM); Ovarian Epithelial Cancer; Severe Hodgkin Lymphoma	CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53	2024-07-25	
Melphalan Flufenamide	Y	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB16627">DB16627</a>	L01AA10	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4303060">CHEMBL4303060</a>	Relapsed Or Refractory Multiple Myeloma	CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53	2024-07-24	
Mercaptopurine	Y	Y	N		Y	1953	Y	<a href="https://go.drugbank.com/drugs/DB01033">DB01033</a>	L01BB02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1425">CHEMBL1425</a>	Acute Lymphoblastic Leukaemias (ALL); Acute Promyelocytic Leukemia (APL); Lymphoma, Lymphoblastic	IDH1; KDM4A; BAZ2B	2024-07-24	
Methotrexate	Y	Y	N		Y	1953	Y	<a href="https://go.drugbank.com/drugs/DB00563">DB00563</a>	L04AX03; L01BA01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL34259">CHEMBL34259</a>	Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer	TYMS; CPT1A; MIR4268; NFATC2; SPECC1L; CDH16; POLB; TNFAIP3; CCND1; GSTM1; ERCC2; NTRK3; GSTT1; ENG; IKZF1; MSH3; CLTC; S100A12; NR1I2; VDR; S100A8; AFP; NQO1; NCOA3; KCNA1; IMPDH1; ADA; HGF; PPARG; NOP2; POLH; NTRK1; GLS; KLRD1; NALCN; FOLH1; CYP2C19; APEX1; CYP2C9; FTCDNL1; DOK5; GATA3; NOS3; PNPLA3; TP53; TLR4; ALOX5; FGFR4; SULT2A1; SLC29A1; HSPB2; SOD2; FLT3; ENOSF1; ICAM3; GSK3B; IDH1; LINC00251; IGHMBP2; SLC22A11; POLI; BIRC5; CYP1A2; FCGR3B; ATF5; SLC28A3; FGF14; HLA-E; BAX; ATP5F1E; KIR2DS4; SLC46A1; BCOR; TARDBP; CDK9; EHMT2; RBMS3; FOLR1; CYP2B6; COL18A1; PYGL; SLAMF1; E2F1; NR3C1; PFDN4; AHRR; KLC3; HSD17B10; MIR3117; SLCO1B1; ATIC; CDH2; CDKN1B; BMP7; CYP2D6; NFATC1; SLC22A8; TAT; DHFR; SLC22A9; ABCC4; FOXP3; CYP3A4; TPM3; ALK; IL2; HLA-C; NFE2L2; SLC16A7; IL1RN; SLC19A1; MPHOSPH8	2024-07-25	
Midostaurin	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB06595">DB06595</a>	L01EX10	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL608533">CHEMBL608533</a>	Acute Myeloid Leukemia (AML); Malignant mast cell neoplasm; Systemic mastocytosis with associated hematological neoplasm	NTRK3; NPM1; PDGFRA; FLT3; STK32B; JAK3; IL6; IDH2; PRKCQ; KDR; PRKCE; DPYS; JAK2; FGFR3; LATS2; PRKCB; CBL; PRKCH; CTSV; PRKCA; PDGFRB; IL2; PIK3CA; PRKD1; FGFR1; JAK1; PRKCI; PIK3CB; TNF; PRKCG; PRKCD; PRKD3; KIT; PRKCZ; HSPA4; YES1	2024-07-24	
Mifamurtide	Y	N	N		N	2009	N	<a href="https://go.drugbank.com/drugs/DB13615">DB13615</a>	L03AX15	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107354">CHEMBL2107354</a>	High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma	NOD2	2024-02-07	
Mirvetuximab Soravtansine	N	Y	N		N	2022	N	<a href="https://go.drugbank.com/drugs/DB12489">DB12489</a>	L01FX26	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545132">CHEMBL3545132</a>	Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer	HOXB2	2024-07-24	
Mitomycin	N	Y	Y		N	1981	Y	<a href="https://go.drugbank.com/drugs/DB00305">DB00305</a>	L01DC03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL105">CHEMBL105</a>	Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; Breast Cancer; Cancer, Anal; Cancer, Bladder; Cervical Cancers; Head and Neck Carcinoma; Mesothelioma; Non-Small Cell Lung Carcinoma (NSCLC); Low-grade Upper Tract Urothelial Cancer (LG-UTUC)	IL1A; PALB2; LGALS2; DHFR; XDH; BRCA1; CYP3A4; CYP1A2; TP53; CYP2C19; AR; CGB5; KRT18; TYMS; VWF; CYP7B1; BGLAP; FANCC; ABCB4; CYP2C9; TAT; MAPK10; CYP2D6; ABCB1	2024-07-25	
Mitoxantrone	N	Y	Y		N	1987	Y	<a href="https://go.drugbank.com/drugs/DB01204">DB01204</a>	L01DB07	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL58">CHEMBL58</a>	Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin&#39;s Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma	UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1	2024-07-24	
Mobocertinib	N	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB16390">DB16390</a>	L01EB10	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650319">CHEMBL4650319</a>	Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer	EGFR	2024-02-07	
Mogamulizumab	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB12498">DB12498</a>	L01FX09	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743041">CHEMBL1743041</a>	Refractory Mycosis Fungoides/Sezary Syndrome; Relapsed Mycosis Fungoides/Sezary Syndrome	CCR4	2024-07-24	
Mosunetuzumab	Y	N	N		N	2022	N	<a href="https://go.drugbank.com/drugs/DB15434">DB15434</a>	L01FX25	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297788">CHEMBL4297788</a>	Relapsed follicular lymphoma, Refractory follicular lymphoma	MS4A1; CD3D; CD3G; CD3E	2024-07-24	
Moxetumomab Pasudotox	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB12688">DB12688</a>	L01FB02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743043">CHEMBL1743043</a>	Relapsed/Refractory Hairy Cell Leukemia	CD22; GNG4; EEF2	2024-07-24	
Nab-Paclitaxel	Y	Y	N		N	2005	Y	<a href="https://go.drugbank.com/drugs/Not found in DrugBank">Not found in DrugBank</a>	L01CD01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL428647">CHEMBL428647</a>	Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi&#39;s sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer	TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A	2024-07-24	
Nab-Sirolimus	N	Y	N		N	2021	Y	<a href="https://go.drugbank.com/drugs/DB00877">DB00877</a>	L04AH01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL413">CHEMBL413</a>	Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)	TP53; TSC1; PIK3CA; IL10; CTLA4; MTOR; ITGAL; CDKN2A; CRLF2; FBXW7; RHEB; FKBP1A; ABCG2; IL17A; NR1I2; NFE2L2; NF1; PTEN; IL15; ABCB1; PLAU; DCN; AR; PGR; TGM2; STK11; APC; EGFR; MMP1; OPRK1; HRAS; FKBP4; IL7; ALK; FGF2; RB1; EML4; WT1; FLCN; NOS1; RPTOR; IGFBP1; BAX; EIF4E; DDC; DDIT3; NRAS; ADAMTSL4-AS1; TCF7L2; ERBB2; RPS6KB1; PIM1; FGFR1; PRKAA1; MAPK10; RBL2; GAPDHP67	2024-07-25	
Nadofaragene Firadenovec	N	Y	N		N	2022	N	<a href="https://go.drugbank.com/drugs/DB17381">DB17381</a>	L01XL10	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3990041">CHEMBL3990041</a>	High risk BCG-unresponsive non-muscle invasive bladder cancer	IFNA2	2024-02-07	
Naxitamab	N	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB15965">DB15965</a>	L01FX21	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297984">CHEMBL4297984</a>	High risk, refractory Neuroblastomas of the bone or bone marrow; High risk, relapsed Neuroblastomas of the bone or bone marrow		2022-10-23	
Necitumumab	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB09559">DB09559</a>	L01FE03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743047">CHEMBL1743047</a>	Metastatic Non-Small Cell Lung Cancer	EGFR; DXO	2024-07-24	
Nelarabine	Y	Y	N		N	2005	Y	<a href="https://go.drugbank.com/drugs/DB01280">DB01280</a>	L01BB07	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201112">CHEMBL1201112</a>	Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory; Refractory Acute Lymphoblastic Leukemia	POLA1; NT5C2	2024-02-07	
Neratinib	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB11828">DB11828</a>	L01EH02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL180022">CHEMBL180022</a>	Breast Cancer	KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2	2024-07-24	
Nilotinib	Y	Y	N		Y	2007	N	<a href="https://go.drugbank.com/drugs/DB04868">DB04868</a>	L01EA03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL255863">CHEMBL255863</a>	Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia	DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1	2024-07-24	
Nilutamide	N	Y	N		N	1996	Y	<a href="https://go.drugbank.com/drugs/DB00665">DB00665</a>	L02BB02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1274">CHEMBL1274</a>	Metastatic Hormone Refractory Prostate Cancer	KLK3; AR; CYP2C9; CYP2D6; NFE2L2; CYP2C19; CYP1A2; PRL; BEVI; CYP3A4	2024-07-24	
Nintedanib	Y	Y	N		N	2014	Y	<a href="https://go.drugbank.com/drugs/DB09079">DB09079</a>	L01EX09	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL502835">CHEMBL502835</a>	Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma	FGFR2; FGFR3; CFLAR; PIK3CA; PDGFRA; FLT1; KIT; KDR; AKT1; DRD1; DPYSL2; CTSV; DPP4; SLC26A3; DRD3; DPYSL3; FLT4; DSP; DR1; FGFR4; FGFR1; PDGFRB; DRD2; DPP6; RET	2024-07-24	
Niraparib	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB11793">DB11793</a>	L01XK02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1094636">CHEMBL1094636</a>	Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer	BRCA1; MYCN; BRCA2; PARP1; GNAI2P1; IDH1; PTEN; ARID1A; ATM; GNAI2; CD274; SLFN11; ATR; PARP2	2024-07-24	
Nirogacestat Hydrobromide	N	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB12005">DB12005</a>	L01XX81	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4298153">CHEMBL4298153</a>	Progressive Desmoid Tumors		2024-02-01	
Nivolumab	Y	Y	N		Y	2015	N	<a href="https://go.drugbank.com/drugs/DB09035">DB09035</a>	L01FF01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108738">CHEMBL2108738</a>	Advanced Renal Cell Cancer; Classical Hodgkin&#39;s Lymphoma; Hepatocellular Carcinoma; Low Risk Advanced Renal Cell Cancer; Melanomas; Metastatic Colorectal Cancer (MCRC); Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Metastatic Small Cell Lung Cancer; Metastatic Squamous Cell Carcinoma of the Head and Neck; Metastatic Urothelial Carcinoma (UC); Recurrent Head and Neck Squamous Cell Carcinoma; Unresectable Melanoma; Intermediate risk Advanced Renal Cell Cancer; Locally advanced Urothelial Carcinoma	FGFR3; CD274; ALK; BRAF; POLE; ATM; PTEN; GM2A; PIK3CA; MLH1; MDM2; PBRM1; EGFR; LAG3; B2M; POLD1; MDM4; ARID1A; MSH2; TP53; IDH1; HLA-DRA; STK11; MSH6; PMS2; NRAS; PDCD1; CDK12; KRAS; ERBB2	2024-07-24	
Obinutuzumab	Y	Y	N		N	2013	N	<a href="https://go.drugbank.com/drugs/DB08935">DB08935</a>	L01FA03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743048">CHEMBL1743048</a>	Refractory Follicular Lymphoma; Previously untreated Chronic lymphocytic leukemia	GATM; TP53; MS4A1	2024-07-24	
Odronextamab	Y	N	N		N	2024		<a href="https://go.drugbank.com/drugs/DB16684">DB16684</a>		<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4298084">CHEMBL4298084</a>	Relapsed/refractory B-Cell non-Hodgkin lymphoma	GATM	2024-07-25	
Ofatumumab	Y	Y	N		N	2009	N	<a href="https://go.drugbank.com/drugs/DB06650">DB06650</a>	L04AA52; L01FA02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201836">CHEMBL1201836</a>	Chronic Lymphocytic Leukaemia (CLL); Chronic Lymphocytic Leukemia (CLL) - Refractory; Progressive Chronic Lymphocytic Leukaemia (CLL); Recurrent Chronic Lymphocytic Leukaemia (CLL)	MS4A1; GATM	2024-07-24	
Olaparib	Y	Y	N		N	2014	N	<a href="https://go.drugbank.com/drugs/DB09074">DB09074</a>	L01XK01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL521686">CHEMBL521686</a>	Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer	PPP2R2A; ESR1; PARP1; FFAR1; PGR; BRAF; ESR2; BRCA2; PALB2; STK11; CHEK2; BRCA1; PTEN; DNMT3A; ARID1A; TET2; IDH1; MYC; ATRX; CDK12; TP53; GNAI2P1; IDH2; HDAC2; NRAS; ERBB2; PARP3; PIK3CA; VHL; ATR; KDM6A; MYCN; BAP1; FANCA; FLT3; SF3B1; RAD54L; BARD1; CHEK1; JAK2; GNAI2; PARP2; ATM; MSH3	2024-07-24	
Olaratumab	Y	Y	N		N	2016	N	<a href="https://go.drugbank.com/drugs/DB06043">DB06043</a>	L01FX10	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743049">CHEMBL1743049</a>	Soft Tissue Sarcoma (STS)	PDGFRA; DPP4	2024-07-24	
Olutasidenib	N	Y	N		N	2022	N	<a href="https://go.drugbank.com/drugs/DB16267">DB16267</a>		<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297610">CHEMBL4297610</a>	Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)	IDH1; GPX1P2	2024-07-24	
Omacetaxine Mepesuccinate	N	Y	N		N	2009	N	<a href="https://go.drugbank.com/drugs/DB04865">DB04865</a>	L01XX40	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL46286">CHEMBL46286</a>	Refractory, accelerated phase Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia	BIRC5; FLT3; TERT; BCR; ABL1	2024-07-24	
Osimertinib	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB09330">DB09330</a>	L01EB04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3353410">CHEMBL3353410</a>	Metastatic Non-Small Cell Lung Cancer	EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS	2024-07-24	
Oxaliplatin	N	Y	Y		Y	2002	Y	<a href="https://go.drugbank.com/drugs/DB00526">DB00526</a>	L01XA03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL414804">CHEMBL414804</a>	Advanced Colorectal Cancer; Advanced Ovarian Cancer; Advanced Pancreatic Cancer; Chronic Lymphocytic Leukemia (CLL) - Refractory; Colon Cancer Stage III; Esophageal Cancers; Malignant Neoplasm of Stomach; Advanced biliary adenocarcinoma; Refractory Neuroendocrine Tumour; Refractory Non-Hodgkin&#39;s lymphoma; Refractory Testicular cancer	DPYD; GSTP1; PARD3B; GNA13; BCL2; BRAF; BRCA1; ABCC1; CD274; DKK1; FOXC2; FGFR2; MLH1; CXCL10; ATP7A; KRAS; ABL1; ABCC5; KCNQ1; IGF2BP2; TP53; PIN1; MTHFR; GCKR; PMS2; ZEB1; SELE; MSH2; BAX; XRCC3; MSH6; PTEN; ATM; PTGS2; CSMD1; ATP7B; KLC3; MGAT4A; PIK3CA; MT1A; ABCC2	2024-07-25	
Paclitaxel	Y	Y	N		Y	1992	Y	<a href="https://go.drugbank.com/drugs/DB01229">DB01229</a>	L01CD01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL428647">CHEMBL428647</a>	Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi&#39;s sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer	TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A	2024-07-24	
Padeliporfin	Y	N	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB15575">DB15575</a>	L01XD07	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4298112">CHEMBL4298112</a>	Low-Risk Prostate Cancer of the one lobe only		2020-09-17	
Palbociclib	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB09073">DB09073</a>	L01EF01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL189963">CHEMBL189963</a>	Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer	MAP4K4; ESR1; CHEK1; LRRK2; CLK2; PIK3CA; CCND2; CCND1; CDK4; MAPK8; PRKAA1; DYRK1B; ERBB2; BRAF; CCND3; TP53; SMARCA4; CDK5; CDK9; CDK6; PGR; CLK4; TAOK1; RB1; PRKD3; CDKN2A; CDKN2B; DAPK3; MAP4K5; DYRK1A; ESR2; KRAS; ROCK2; ALK; MET; PAK4; RPS6KA3; MAPK9; CCNE2; RET; NEK2; NRAS; MAP4K2; CCNE1; EIF4EBP1; PRKX; PTEN; MST1R; FLT3	2024-07-24	
Panitumumab	Y	Y	N		N	2006	N	<a href="https://go.drugbank.com/drugs/DB01269">DB01269</a>	L01FE02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201827">CHEMBL1201827</a>	Metastatic Colorectal Cancer (MCRC)	NRAS; NRG2; EGFR; TGFA; CDKN2A; KRAS; AREG; NRG3; MET; TP53; NRG1; PTEN; DXO; PIK3CA; BTC; HBEGF; BRAF; EREG; HRAS; MAP2K1	2024-07-24	
Panobinostat	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB06603">DB06603</a>	L01XH03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL483254">CHEMBL483254</a>	Refractory Multiple Myeloma	HDAC1; GDF2; HDAC3; SIRT3; SMARCB1; SIRT1; HDAC2; HDAC8; HDAC9; HDAC4; BRAF; SIRT4; GAPDHP1; MYCN; HDAC10; SIRT2; SIRT5; GARS1; HDAC6; BAP1; CSF1R; HDAC7; SIRT7; ACTL6A; HDAC11; GAS1; HDAC5; SIRT6; GDF9; IDH1; GART; GAS2; KMT2A	2024-07-24	
Pazopanib	Y	Y	N		N	2009	Y	<a href="https://go.drugbank.com/drugs/DB06589">DB06589</a>	L01EX03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL477772">CHEMBL477772</a>	Advanced Renal Cell Carcinoma; Advanced Soft Tissue Sarcoma; Advanced Thyroid cancer	VHL; KDR; DPYSL2; FGFR1; FGFR2; FLT4; KIT; HFE; PDGFRB; NEK2; HIF1A; TP53; DRD3; ALK; CSF1R; VEGFA; NR1I2; DPYD; NRAS; CDK7; MTOR; LIMK1; ABL1; PDGFRA; AURKA; MAPK9; LCK; DRD2; ITK; MAPK8; UGT1A1; NF1; RET; DRD1; CYP3A4; PBRM1; DPT; AURKB; LTK; MAP4K4; HLA-B; HDAC2; PPARD; TAOK1; DPP6; EWSR1; AR; CYP2C8; PTK2; FYN; SCGB3A1; CXCL8; IGF1R; FLT1; MET; FGFR3; YES1; TNK2	2024-07-25	
Pegaspargase	Y	Y	N		Y	1994	N	<a href="https://go.drugbank.com/drugs/DB00059">DB00059</a>	L01XX24	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108546">CHEMBL2108546</a>	Acute Lymphoblastic Leukaemias (ALL)	HLA-DRB1; APOC3; HLA-DQA1; TPMT; CPT1A; PNPLA3; UGT1A1; ARHGAP28; BMP7; IGHMBP2; LINC00251; DOK5; GATA3; HLA-DQB1; APOA5	2024-07-24	
Peginterferon Alfa-2b	Y	Y	N		N	2001	N	<a href="https://go.drugbank.com/drugs/DB00022">DB00022</a>	L03AB10	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201561">CHEMBL1201561</a>	Melanomas	DHODH; IFIT1; IL6; EGFR; JAK2; MICB; HLA-DPA1; CARD16; CTLA4; IFNAR2; CXCL10; OAS1; IFNL3; IFNA2; IL21R; CASP1; IFNAR1; IL18; KLRK1; SLC29A1; VDR; KIR2DS2; SLC6A4; HLA-A; OASL; DNAAF9; SLC28A2; SOCS3; HLA-C; CYP2R1; TUT7; HLA-B	2024-07-24	
Pembrolizumab	Y	Y	N		Y	2014	N	<a href="https://go.drugbank.com/drugs/DB09037">DB09037</a>	L01FF02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3137343">CHEMBL3137343</a>	Advanced Renal Cell Carcinoma; Cervical Cancers; Colorectal Cancers; Metastatic Melanoma; Metastatic Solid Tumors; Unresectable Melanoma; Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma; Locally advanced gastroesphageal juntion adenocarcinoma; Metastatic gastroesphageal juntion adenocarcinoma; Metastatic nonsquamous non-small cell lung cancer; Recurrent, metastatic Head and Neck Squamous Cell Carcinoma; Refractory, metastatic Non small cell lung cancer; Refractory, relapsed Hodgkin Lymphoma; Refractory, relapsed Mediastinal Large B-cell Lymphoma; Unresectable Solid Tumors	ARID1A; EGFR; JAK1; ROS1; POLE; PBRM1; KEAP1; MSH2; PDCD1; MDM4; GM2A; BRAF; FBXW7; JAK2; ERBB2; PDCD1LG2; CD274; MLH1; TP53; PTEN; KIT; KRAS; STK11; MSH6; ALK; IDH1; B2M; POLD1; CDK12; PMS2; NRAS; MDM2; MET; PIK3CA; HLA-DRA	2024-07-24	
Pemetrexed	Y	Y	N		N	2004	Y	<a href="https://go.drugbank.com/drugs/DB00642">DB00642</a>	L01BA04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL225072">CHEMBL225072</a>	Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma	RRM1; CAMKK2; DHFR; EGFR; ALK; TYMS; VEGFA; SLC22A8; ATIC; SLC46A1; GCGR; ROS1; MTHFR; CD274; GART; KRAS; FOLR3; GGH; EXO1; PTEN; MTHFD1; XRCC1; ABCC2; ERCC2; SLC19A1	2024-07-25	
Pemigatinib	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB15102">DB15102</a>	L01EN02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297522">CHEMBL4297522</a>	Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas	FGFR3; FGFR2; DPYSL3; DR1; DPYSL2; FGFR1	2024-07-24	
Pentostatin	N	N	Y		N	1991	Y	<a href="https://go.drugbank.com/drugs/DB00552">DB00552</a>	L01XX08	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1580">CHEMBL1580</a>	B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory; Chronic Lymphocytic Leukaemia (CLL); Hairy Cell Leukemia (HCL); Mycosis Fungoides (MF); Sezary Syndrome	CCR1; PRKAA1; ADA	2024-07-24	
Pertuzumab	Y	Y	N		N	2012	N	<a href="https://go.drugbank.com/drugs/DB06366">DB06366</a>	L01FD02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2007641">CHEMBL2007641</a>	Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer		2024-07-24	
Pertuzumab, Trastuzumab, Hyaluronidase	Y	Y	N		N	2020		<a href="https://go.drugbank.com/drugs/Not found in DrugBank">Not found in DrugBank</a>	L01XY02				2021-10-28	
Pipobroman	N	N	Y		N	1966		<a href="https://go.drugbank.com/drugs/DB00236">DB00236</a>	L01AX02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1585">CHEMBL1585</a>		NFE2L2; KDM4E; ALDH1A1	2024-07-24	
Pirarubicin	N	N	N	Japan	N			<a href="https://go.drugbank.com/drugs/DB11616">DB11616</a>	L01DB08	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2354444">CHEMBL2354444</a>		ABCC1; KMT2A; POLK; MYCN; FEN1; TP53; GLS; HTT; USP1	2024-07-24	
Pirtobrutinib	Y	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB17472">DB17472</a>	L01EL05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650485">CHEMBL4650485</a>	Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma	BTK; TP53; EFNB2; IGH	2024-07-24	
Pixantrone	Y	N	N		N	2012	N	<a href="https://go.drugbank.com/drugs/DB06193">DB06193</a>	L01DB11	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL167731">CHEMBL167731</a>	Non-Hodgkin&#39;s Lymphoma, Relapsed; Refractory Non-Hodgkin&#39;s lymphoma	TOP2A	2024-02-07	
Polatuzumab Vedotin	Y	Y	N		N	2019	N	<a href="https://go.drugbank.com/drugs/DB12240">DB12240</a>	L01FX14	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3301582">CHEMBL3301582</a>	Diffuse Large B-Cell Lymphoma (DLBCL)	CD79B; TUBB4A; TUBB8; TUBA1B; TUBB4B; BCL6; BCL2; TUBB2A; TUBB; TUBA3E; TUBA1C; TUBB3; TUBB6; TUBB2B; TUBB1; TUBA1A; TUBA3C; MYC; TUBA4A	2024-07-24	
Polyestradiol Phosphate	N	N	Y		N	1957		<a href="https://go.drugbank.com/drugs/DB09369">DB09369</a>	L02AA02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201477">CHEMBL1201477</a>		ESR1; NOS1; AFP	2024-07-24	
Pomalidomide	Y	Y	N		N	2013	Y	<a href="https://go.drugbank.com/drugs/DB08910">DB08910</a>	L04AX06	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL43452">CHEMBL43452</a>	Refractory Multiple Myeloma	CRBN; RBX1; CUL4A; DDB1	2024-07-24	
Ponatinib	Y	Y	N		N	2012	N	<a href="https://go.drugbank.com/drugs/DB08901">DB08901</a>	L01EA05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1171837">CHEMBL1171837</a>	Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia	FGFR1; ABL1; FLT3; CDK19; FAP; FGFR3; BCR; PDGFRA; ABL2; FGFR2; KRAS; PDGFRB; ABI1; KIT; EIF4EP1; EML4; FANCG; SRC; PTK2B; RIPK2; YES1; FGFR4; BRAF; KDR; RET	2024-07-24	
Porfimer	Y	Y	N		N	1995	N	<a href="https://go.drugbank.com/drugs/DB00707">DB00707</a>	L01XD01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201481">CHEMBL1201481</a>	Esophageal Cancers; Completely obstructive Non-small cell lung cancer; Microinvasive endobrachial Non-small cell lung cancer; Partially obstructive Non-small cell lung cancer		2020-09-17	
Pralatrexate	Y	Y	N		N	2009	Y	<a href="https://go.drugbank.com/drugs/DB06813">DB06813</a>	L01BA05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201746">CHEMBL1201746</a>	Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified	DHFR; PDF; RFC1	2024-07-24	
Pralsetinib	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB15822">DB15822</a>	L01EX23	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297597">CHEMBL4297597</a>	Metastatic RET-fusion Non Small Cell Lung Cancer	EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET	2024-07-24	
Prednisolone	Y	Y	N		Y	1955	Y	<a href="https://go.drugbank.com/drugs/DB00860">DB00860</a>	S03BA02; S02BA03; S01CB02; S01BA04; R01AD02; H02AB06; D07XA02; D07AA03; C05AA04; A07EA01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL131">CHEMBL131</a>	Hypercalcemia of Malignancy; Leukemia, Acute; Malignant Lymphomas; Mycosis Fungoides (MF)	LCAT; PNPLA3; CYP3A4; ALPP; NR3C1; DSE; NFE2L2; FCGR3A; FCGR3B; CYBA; MTHFR; TSPYL1; GATA3; AR; RAC2; NR3C2; CYP3A5; BDM; TAT; G6PD; HMGB1; BGLAP; RPS19; CD34; PLG; TG; ANXA1; BAX	2024-07-25	
Prednisone	N	Y	Y		N	1955	Y	<a href="https://go.drugbank.com/drugs/DB00635">DB00635</a>	H02AB07; A07EA03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL635">CHEMBL635</a>	Acute Lymphoblastic Leukaemias (ALL); Aggressive Lymphoma; Hypercalcemia of Malignancy; Leukemia, Acute; Leukemias; Malignant Lymphomas; Metastatic Castration Resistant Prostate Cancer; Mycosis Fungoides (MF)	BMP7; TYMS; GSTM1; GSTP1; MIR4268; MC2R; NOS3; DOK5; ITGB2; TG; CXCL12; CYP3A5; CALCA; CYP3A4; VWF; MIR3117; CYP2C9; SLC19A1; TYMSOS; GSTA1; TPMT; IFNG; CYP1A2; GATA3; PTPRC; APOE; LINC00251; NCF4; AR; MYC; MBP; HSD17B10; NR3C1; NFATC1; CTLA4; CYBA; EDNRA; ABCB1; ATF5; BDM; ANXA1; CYP2D6; CYP2C19	2024-07-25	
Procarbazine	N	Y	Y		Y	1969	N	<a href="https://go.drugbank.com/drugs/DB01168">DB01168</a>	L01XB01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1321">CHEMBL1321</a>	Non-Hodgkin&#39;s Lymphoma (NHL); Oligodendrogliomas; Primary Central Nervous System Lymphoma (PCNSL); Stage III Hodgkin&#39;s Disease; Stage IV Hodgkin&#39;s Disease	CYP1A2; BAX; EPM2AIP1; CSF2; ALOX15	2024-07-24	
Quizartinib	Y	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB12874">DB12874</a>	L01EX11	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/ CHEMBL576982"> CHEMBL576982</a>	Newly Diagnosed Acute Myeloid Leukemia (AML)	DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2	2024-07-24	
Racotumomab	N	N	N	Cuba, Argentina	N			<a href="https://go.drugbank.com/drugs/DB13045">DB13045</a>		<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743059">CHEMBL1743059</a>			2020-09-17	
Radium 223 Dichloride	Y	Y	N		N	2013	N	<a href="https://go.drugbank.com/drugs/DB08913">DB08913</a>	V10XX03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107816">CHEMBL2107816</a>	Castration resistant, metastatic Prostate cancer		2020-09-17	
Raltitrexed	N	N	Y	Canada	N	1996	N	<a href="https://go.drugbank.com/drugs/DB00293">DB00293</a>	L01BA03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL225071">CHEMBL225071</a>	Advanced Colorectal Cancer; Pleural Mesotheliomas	CDK2; TYMS; CDKN1B; SLC19A1; ALB; GCGR; DHFR	2024-07-24	
Ramucirumab	Y	Y	N		N	2014	N	<a href="https://go.drugbank.com/drugs/DB05578">DB05578</a>	L01FG02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743062">CHEMBL1743062</a>	Advanced Gastric Cancer; Advanced gastro-esophageal junction adenocarcinoma; Refractory, metastatic Colorectal cancer; Refractory, metastatic Non small cell lung cancer	KDR; PDGFRA; EGFR; KRAS; DRD2; ALK	2024-07-24	
Ranimustine	N	N	N	Japan	N			<a href="https://go.drugbank.com/drugs/DB13832">DB13832</a>	L01AD07	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105348">CHEMBL2105348</a>			2020-09-22	
Realgar-Indigo Naturalis Formulation	N	N	N	China	Y	2009		<a href="https://go.drugbank.com/drugs/Not found in DrugBank">Not found in DrugBank</a>	L01XX27		Acute promyelocytic leukaemia		2021-03-10	
Regorafenib	Y	Y	N		N	2012	N	<a href="https://go.drugbank.com/drugs/DB08896">DB08896</a>	L01EX05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1946170">CHEMBL1946170</a>	Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor	PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4	2024-07-24	
Relatlimab ,  Nivolumab	Y	Y	N		N	2022		<a href="https://go.drugbank.com/drugs/DB14851">DB14851</a>	L01XY03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3990044">CHEMBL3990044</a>; <a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108738">CHEMBL2108738</a>	Metastatic Melanoma, Unresectable Melanoma		2024-07-25	
Relugolix	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB11853">DB11853</a>	L02BX04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1800159">CHEMBL1800159</a>	Advanced Prostate Cancer	GNRHR; LHCGR	2024-02-07	
Repotrectinib	N	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB16826">DB16826</a>	L01EX28	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4298138">CHEMBL4298138</a>	locally active or metastatic non-small cell lung cancer	EML4; NTRK3; ALK; ROS1; DTX1; NTRK1; DRG2; EPHB2; DRD5P2; HBEGF; DRD5P1	2024-07-24	
Retifanlimab	Y	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB15766">DB15766</a>	L01FF10	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4298037">CHEMBL4298037</a>	Metastatic Locally Advanced Merkel Cell Carcinoma, Recurrent, locally advanced Merkel Cell Carcinoma	GM2A	2024-07-24	
Ribociclib	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB11730">DB11730</a>	L01EF02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545110">CHEMBL3545110</a>	Advanced Breast Cancer; Metastatic Breast Cancer	CDK4; PIK3CA; PGR; CCND3; ALK; RB1; JAK2; ERBB2; ESR1; NRAS; CCND1; CCND2; SMARCA4; BRAF; CDK6; ESR2; PTEN; CDKN2A	2024-07-24	
Ripretinib	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB14840">DB14840</a>	L01EX19	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4216467">CHEMBL4216467</a>	Advanced Gastrointestinal Stromal Tumor (GIST)	CYP3A4; KIT; PDGFRB; PDGFRA; DPT	2024-07-24	
Rituximab	Y	Y	N		Y	1997	N	<a href="https://go.drugbank.com/drugs/DB00073">DB00073</a>	L01FA01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201576">CHEMBL1201576</a>	Chronic Lymphocytic Leukaemia (CLL); Non-Hodgkin&#39;s Lymphoma (NHL)	ABCB1; ERBB2; TET2; MS4A1; KRAS; FCGR3A; CYBA; ARID1A; IFNG; IL2; NCF4; GATM; CD274; RPS19; PIK3CA; TGFB1; CD38; EGFR; EN1; GMPR; JAK2; PIK3CG; PGR; EPCAM; NRG1; CBR3; PPCDC; IL6; MET; ANXA1; TP53; FCGR2A; GSTA1; HSPB2; CXCL12; AKT2; XIAP; RNF8; HGF; ESR1; ERBB3; CXCL13; PTEN; BIRC5; ESR2	2024-07-24	
Rituximab, Hyaluronidase	N	Y	N		N	1997	N	<a href="https://go.drugbank.com/drugs/DB00073">DB00073</a>	L01XC02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201576">CHEMBL1201576</a>	Chronic Lymphocytic Leukaemia (CLL); Non-Hodgkin&#39;s Lymphoma (NHL)	ABCB1; ERBB2; TET2; MS4A1; KRAS; FCGR3A; CYBA; ARID1A; IFNG; IL2; NCF4; GATM; CD274; RPS19; PIK3CA; TGFB1; CD38; EGFR; EN1; GMPR; JAK2; PIK3CG; PGR; EPCAM; NRG1; CBR3; PPCDC; IL6; MET; ANXA1; TP53; FCGR2A; GSTA1; HSPB2; CXCL12; AKT2; XIAP; RNF8; HGF; ESR1; ERBB3; CXCL13; PTEN; BIRC5; ESR2	2024-07-24	
Romidepsin	Y	Y	N		N	2009	Y	<a href="https://go.drugbank.com/drugs/DB06176">DB06176</a>	L01XH02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL343448">CHEMBL343448</a>	Refractory peripheral cutaneous T-cell lymphoma	BRAF; HDAC1; HDAC10; CDKN2D; HDAC5; GDF2; HDAC4; GAS2; HDAC6; ADAMTSL4-AS1; HDAC2; GDF9; ERBB2; KMT2A; GART; MSTN; GAPDHP1; HDAC8; HDAC9; ABCB1; GAS1; GARS1; CDKN1A; CTAG1B; HDAC3; HDAC11; BIRC5; HDAC7	2024-07-24	
Rucaparib	Y	Y	N		N	2016	N	<a href="https://go.drugbank.com/drugs/DB12332">DB12332</a>	L01XK03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1173055">CHEMBL1173055</a>	Advanced Ovarian Cancer	PARP2; PARP1; PRKD2; BRCA1; CDK12; ATM; CDK1; IDH1; PALB2; CYP2D6; NRAS; DYRK1A; ARID1A; CYP1A2; ATR; PIM1; PTEN; YES1; BRCA2; BRAF; PARP3; GNAI2	2024-07-24	
Ruxolitinib	Y	Y	N		N	2011	N	<a href="https://go.drugbank.com/drugs/DB08877">DB08877</a>	L01EJ01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1789941">CHEMBL1789941</a>	Post Polycythemia Vera Myelofibrosis; Refractory Polycythemia vera	JAK2; SH2B3; CSF3R; JAK3; JAK1; PLAUR; VHL; CRLF2; EPHB3; EPHB2; BRAF; CYP3A4; EPHB1; TYK2; IL7R; TP53; FLT3	2024-07-24	
Sacituzumab Govitecan	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB12893">DB12893</a>	L01FX17	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545262">CHEMBL3545262</a>	Metastatic Triple-negative Breast Cancer	ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2	2024-07-24	
Selinexor	Y	Y	N		N	2019	N	<a href="https://go.drugbank.com/drugs/DB11942">DB11942</a>	L01XX66	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545185">CHEMBL3545185</a>	Refractory Multiple Myeloma	FLT3; TET2; TP53; XPO1; H2AX	2024-07-24	
Selpercatinib	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB15685">DB15685</a>	L01EX22	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4559134">CHEMBL4559134</a>	Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer	RET; KIF5B; PTK2B; CCDC6	2024-07-24	
Sipuleucel-T	N	Y	N		N	2010	N	<a href="https://go.drugbank.com/drugs/DB06688">DB06688</a>	L03AX17	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1237024">CHEMBL1237024</a>	Asymptomatic, metastatic hormone-refractory Prostate cancer; Minimally symptomatic, metastatic hormone-refractory Prostate cancer	ACP3	2024-02-07	
Sonidegib	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB09143">DB09143</a>	L01XJ02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105737">CHEMBL2105737</a>	Refractory, locally advanced Basal cell carcinoma	PTCH1; SMO; ALOX12; SUFU; FLT3; MYCN	2024-07-24	
Sorafenib	Y	Y	N		N	2005	Y	<a href="https://go.drugbank.com/drugs/DB00398">DB00398</a>	L01EX02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1336">CHEMBL1336</a>	Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma	DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7	2024-07-24	
Sotorasib	Y	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB15569">DB15569</a>	L01XX73	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4535757">CHEMBL4535757</a>	Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer	KRAS; HRAS; NRAS	2024-07-24	
Streptozocin	N	Y	N		N	2005	N	<a href="https://go.drugbank.com/drugs/DB00428">DB00428</a>	L01AD04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1651906">CHEMBL1651906</a>	Stage 4 islet cell carcinoma	SI; IGFBP1; DDIT3; S100B; SSTR1; CYP7B1; CSF2; TRPV1; TH; CTSD; PTGER4; HRAS; OGA; TGFB1; THRSP; SULT1A2; CD40; BCL2; ATF2; ADCYAP1; CDKN1B; ACP5; GALP; CYP2D6; VWF; KCNJ11; UCP1; LCAT; HGF; SLC2A4; SLC5A1; RAMP3; KCNA2; MT1H; NTRK1; HP; MMP2; PRKAA1; SLC2A5; SFTPB; SST; PREP; MYO9B; ENO2; PIK3CA; SLC16A3	2024-07-24	
Sugemalimab	Y	N	N		N	2024		<a href="https://go.drugbank.com/drugs/DB16641">DB16641</a>	L01FF11	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594535">CHEMBL4594535</a>	Metastatic non-small cell lung cancer (NSCLC)		2024-07-25	
Sunitinib	Y	Y	N		N	2006	Y	<a href="https://go.drugbank.com/drugs/DB01268">DB01268</a>	L01EX01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL535">CHEMBL535</a>	Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors	FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1	2024-07-25	
Tafasitamab	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB15044">DB15044</a>	L01FX12	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4298047">CHEMBL4298047</a>	Refractory Diffuse large B-cell lymphoma NOS; Relapsed Diffuse large B-cell lymphoma NOS	GMFB; TNFRSF8; CD19	2024-07-24	
Tagraxofusp	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB14731">DB14731</a>	L01XX67	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297573">CHEMBL4297573</a>	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)	CSF2RB; EEF2; IL3RA	2024-07-24	
Talazoparib	Y	Y	N		N	2018	N	<a href="https://go.drugbank.com/drugs/DB11760">DB11760</a>	L01XK04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3137320">CHEMBL3137320</a>	Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer	MYCN; CDK12; MLH1; STK11; BRCA2; FLT3; SLFN11; PARP2; ATRX; GNAI2; ATR; BRAF; GNAI2P1; PSMD4; PARP1; NRAS; ARID1A; IDH1; EGFR; DNMT3A; ERBB2; IDH2; ATM; BRCA1; TET2; PALB2; PTEN	2024-07-24	
Talimogene Laherparepvec	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB13896">DB13896</a>	L01XX51	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108727">CHEMBL2108727</a>	Unresectable Skin Lesion	CSF2; CSF2RA	2024-07-24	
Talquetamab	Y	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB16678">DB16678</a>	L01FX29	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594503">CHEMBL4594503</a>	Relapsed and Refractory Multiple Myeloma	CD3G; GPRC5D; CD3E; CD3D	2024-07-24	
Tamoxifen	N	Y	Y		Y	1977	Y	<a href="https://go.drugbank.com/drugs/DB00675">DB00675</a>	L02BA01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL83">CHEMBL83</a>	Breast Cancer; Desmoid Tumors; Endometrial Cancer; Invasive Breast Cancer; Invasive Breast Carcinoma; Metastatic Breast Cancer; Ovarian Cancer	AURKA; ESR1; PGR; FMO3; ATXN2; ESR2; HSPB2; COL18A1; VDR; HEXB; PLD1; EHMT2; CYP2C9; MUC16; ERBB2; RRAS2; SLCO1A2; NFE2L2; NCOA3; NF1; TFF3; CYP2B6; CYP2D6; TP53; FMO1; CYP19A1; EDN1; PLD2; PIP; ZNF613; F2; E2F7; BRCA1; LRMDA; NR1I2; BAZ2B; ALDH3B1; CBX1; GGT1; GMNN; CCND1; MYOD1; DHFR; CYP1A2; SLCO2B1; KLK3; PIK3CA; UGT1A4; BCYRN1P2; NCOA1; NRG1; CETP; CYP3A4; ZNF423; CCNA2; TGM2; IGF1R; IDH1; NTRK1; GAPDH; KDM4A; BGLAP; TYMS; F5; TGFB1	2024-07-24	
Tarlatamab	N	Y	N		N	2024	N	<a href="https://go.drugbank.com/drugs/DB17256">DB17256</a>	L01FX33	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5095292">CHEMBL5095292</a>	Extensive-stage small cell lung cancer	GLRA2	2024-07-24	
Tazemetostat	N	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB12887">DB12887</a>	L01XX72	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3414621">CHEMBL3414621</a>	Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma	SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A	2024-07-24	
Tebentafusp	Y	Y	N		N	2022	N	<a href="https://go.drugbank.com/drugs/DB15283">DB15283</a>	L01XX75	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297990">CHEMBL4297990</a>	Metastatic Uveal Melanoma (UM), Unresectable Uveal Melanoma	PMEL; TRBV20OR9-2; HLA-A; CD3G	2024-07-24	
Teclistamab	Y	Y	N		N	2022	N	<a href="https://go.drugbank.com/drugs/DB16655">DB16655</a>	L01FX24	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594505">CHEMBL4594505</a>	Multiple Myeloma	CD3D; CD3E; CD3G; TNFRSF17	2024-07-24	
Tegafur, Gimeracil, Oteracil	Y	N	N		N	2011		<a href="https://go.drugbank.com/drugs/DB09256">DB09256</a>	L01BC03; L01BC53	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL20883">CHEMBL20883</a>	Advanced Gastric Cancer	TYMP	2024-07-24	
Tegafur, Uracil	N	N	N	Japan	N			<a href="https://go.drugbank.com/drugs/DB09256">DB09256</a>	L01BC03; L01BC53	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL20883">CHEMBL20883</a>	Advanced Gastric Cancer	TYMP	2024-07-24	
Temoporfin	Y	N	N		N	2001	N	<a href="https://go.drugbank.com/drugs/DB11630">DB11630</a>	L01XD05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL500576">CHEMBL500576</a>	Advanced Head and Neck Squamous Cell Carcinoma		2020-09-17	
Temozolomide	Y	Y	N		N	1999	Y	<a href="https://go.drugbank.com/drugs/DB00853">DB00853</a>	L01AX03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL810">CHEMBL810</a>	Advanced Melanoma; Glioblastomas; Primary Central Nervous System Lymphoma (PCNSL); Refractory Ewing Sarcoma; Refractory Neuroblastoma; Soft Tissue Sarcoma (STS); Advanced Neuroendocrine tumor; Refractory Anaplastic astrocytoma; Refractory, advanced Mycosis fungoides; Refractory, advanced Sezary Syndrome	PIK3CA; MGMT; HDAC4; PTEN; ATRX; TP53; MYC; IDH1; H2AX; BRCA2; GSTP1; CDKN2A; ATR; PRL; MSH6; CSF2; ALK; ARID1A; ATM; SLFN11	2024-07-24	
Temsirolimus	Y	Y	N		N	2007	Y	<a href="https://go.drugbank.com/drugs/DB06287">DB06287</a>	L01EG01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201182">CHEMBL1201182</a>	Advanced Renal Cell Carcinoma	NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD	2024-07-24	
Tepotinib	Y	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB15133">DB15133</a>	L01EX21	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3402762">CHEMBL3402762</a>	Metastatic Non-Small Cell Lung Cancer	MET; EGFR; DRD4; ALK	2024-07-24	
Thalidomide	Y	Y	N		Y	1998	N	<a href="https://go.drugbank.com/drugs/DB01041">DB01041</a>	L04AX02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL468">CHEMBL468</a>	Multiple Myeloma (MM); Waldenstrom&#39;s Macroglobulinemia (WM); Treatment naive multiple myeloma	FCGR3B; FGFR2; DDB1; CRBN; F2R; RBX1; FCGR3A; TNF; CYP1A2; RPL13; ABCC6; NFKB1; SPG7; XRCC5; ATP7A; CYP4B1; VEGFA; SULT1C4; PTGS2; HLA-B; FGF2; VWF; CUL4A; CHST3; MECOM; NAT2; HGF; ERCC1; CTLA4; SLC10A2; CYP2C19; ITGB2; CTNNB1; IL6R; GSTT1; SNORD68; PPARD	2024-07-24	
Thioguanine	N	Y	N		N	1966	N	<a href="https://go.drugbank.com/drugs/DB00352">DB00352</a>	L01BB03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL727">CHEMBL727</a>	Acute Nonlymphocytic Leukemia; Nonlymphocytic Acute myeloid leukemia	KDM4A; CPT1A; GDA; GATA2; LINC00251; GGH; HPGD; IGHMBP2; MGMT; NUDT15; PNPLA3; EHMT2; UGT1A1; NAT1; PAX8; GATA3; BMP7; TPMT; XDH; NFE2L2; IMPDH1; PRPS1; ACHE; IMPDH2; NT5C2; DOK5; MYC; IDH1; HBB; SLC28A3; AR; TPM3; ABCC4	2024-07-24	
Thiotepa	Y	Y	N		N	1959	Y	<a href="https://go.drugbank.com/drugs/DB04572">DB04572</a>	L01AC01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL671">CHEMBL671</a>	Adenocarcinoma of the Ovaries; Breast Adenocarcinoma; Papillary transitional cell carcinoma of bladder; Malignant effusion	TP53; HPGD; GMNN; ALDH1A1; CYP2B6; EHMT2; VDR; GSTP1; ALDH3A1; AR	2024-07-24	
Tisagenlecleucel	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB13881">DB13881</a>	L01XX71	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3301574">CHEMBL3301574</a>	Refractory B-cell precursor acute lymphoblastic leukemia; Second or later relapsed B-cell precursor acute lymphoblastic leukemia	MS4A1; CD19	2024-07-24	
Tislelizumab	Y	N	N	China	N	2023	N	<a href="https://go.drugbank.com/drugs/DB14922">DB14922</a>	L01FF09	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297840">CHEMBL4297840</a>	Unresectable, Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	GM2A	2024-07-25	
Tisotumab Vedotin	N	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB16732">DB16732</a>	L01FX23	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297841">CHEMBL4297841</a>	Recurrent or metastatic cervical cancer	TUBB1; F3; TUBA1B; TUBB8; TUBA3E; TUBB2A; TUBB6; TUBB2B; TUBA4A; TUBB; TUBA1C; TUBB4B; TUBA3C; TUBB3; TUBA1A; TUBB4A	2024-07-24	
Tivozanib	Y	Y	N		N	2017	N	<a href="https://go.drugbank.com/drugs/DB11800">DB11800</a>	L01EK03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1289494">CHEMBL1289494</a>	Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma	FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3	2024-07-24	
Topotecan	Y	Y	N		N	1996	Y	<a href="https://go.drugbank.com/drugs/DB01030">DB01030</a>	L01CE01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL84">CHEMBL84</a>	Acute Myeloid Leukemia (AML); Ewing&#39;s Sarcoma; Refractory Neuroblastoma; Metastatic Rhabdomyosarcoma; Recurrent, IV-B Cervical cancer; Refractory CNS lymphoma; Refractory CNS malignancy; Refractory, metastatic Ovarian cancer; Relapsed Small cell lung cancer	DDO; PAX8; IDH1; ABCG2; AR; PLK1; TOP1; ALK; KMT2A; HIF1A; HBB; TSG101; ABCB1; AKT1; TYMS; RB1; TOP1MT; NFE2L2; MDM2; USP1; PTEN; TP53; PIK3CA; BDNF; MUC16	2024-07-24	
Toremifene	Y	Y	N		N	1997	Y	<a href="https://go.drugbank.com/drugs/DB00539">DB00539</a>	L02BA02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1655">CHEMBL1655</a>	Desmoid Tumors; Metastatic Breast Cancer	CYP1B1; ESR1; ESR2; CYP3A4; TGFB1; HNF4A; AR; CYP2D6; PGR; PLIN1; KDM4A; GMNN; CD80	2024-07-24	
Toripalimab	N	Y	N		N	2023	N	<a href="https://go.drugbank.com/drugs/DB15043">DB15043</a>	L01FF13	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297843">CHEMBL4297843</a>	Metastatic and Recurrent Nasopharyngeal Carcinoma	GM2A	2024-07-24	
Tovorafenib	N	Y	N		N	2024	N	<a href="https://go.drugbank.com/drugs/DB15266">DB15266</a>		<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3348923">CHEMBL3348923</a>	Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation	RAF1; BRAF; ARAF; EFNA2; ZHX2	2024-07-24	
Trabectedin	Y	Y	N		N	2015	N	<a href="https://go.drugbank.com/drugs/DB05109">DB05109</a>	L01CX01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL450449">CHEMBL450449</a>	Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Relapsed platinum-sensitive Ovarian cancer; Unresectable Leiomyosarcoma; Unresectable Liposarcoma	PARP1; TP53; ABCC2; ABCB1; CD274; FGFR2	2024-07-24	
Trametinib	Y	Y	N		N	2013	N	<a href="https://go.drugbank.com/drugs/DB08911">DB08911</a>	L01EE01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103875">CHEMBL2103875</a>	Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric  low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation	ETV5; BRAF; KRAS; FGFR1; MAP2K1; MAP2K2; TP53; NF1; PRKCH; RAF1; ABL1; ATM; MAP2K5; APC; ERBB3; G6PD; CDKN2A; KEAP1; ARAF; ETV4; RB1; ETV1; MET; VHL; MAP2K6; MAP2K4; DNMT3A; RET; KIT; MDM2; PIK3CA; EML4; PTEN; CD274; ATXN1L; NR2F6; ALK; MAP2K3; CIC; DDX43; RASA1; STK11; FLT3; HRAS; NRAS; CSF3R; CTNNB1; FGFR2; DUSP6; MAP2K7	2024-07-24	
Trastuzumab	Y	Y	N		Y	1998	N	<a href="https://go.drugbank.com/drugs/DB00072">DB00072</a>	L01FD01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201585">CHEMBL1201585</a>	Breast Cancer; Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Adenocarcinoma of the Gastro-Esophageal Junction; Metastatic Adenocarcinoma of the Stomach; Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma	ERBB2	2024-07-24	
Trastuzumab Deruxtecan	Y	Y	N		N	2019	N	<a href="https://go.drugbank.com/drugs/DB14962">DB14962</a>	L01FD04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297844">CHEMBL4297844</a>	HER2 Positive Breast Cancers	ESR1; TOP1; ESR2; ERBB2	2024-07-24	
Trastuzumab Emtansine	Y	Y	N		N	2013	N	<a href="https://go.drugbank.com/drugs/DB05773">DB05773</a>	L01FD03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743082">CHEMBL1743082</a>	Refractory, metastatic Non small cell lung cancer	ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8	2024-07-24	
Trastuzumab, Hyaluronidase	Y	Y	N		N	1998	N	<a href="https://go.drugbank.com/drugs/DB00072">DB00072</a>	L01XC03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201585">CHEMBL1201585</a>	Breast Cancer; Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Adenocarcinoma of the Gastro-Esophageal Junction; Metastatic Adenocarcinoma of the Stomach; Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma	ERBB2	2024-07-24	
Tremelimumab	Y	Y	N		N	2022	N	<a href="https://go.drugbank.com/drugs/DB11771">DB11771</a>	L01FX20	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108658">CHEMBL2108658</a>	Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)	CTLA4; MSH6; CD274; GLRB; PMS2; MLH1; ALK; EGFR; MSH2	2024-07-24	
Tretinoin	N	Y	Y		N	1971	Y	<a href="https://go.drugbank.com/drugs/DB00755">DB00755</a>	D10AD01; L01XF01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL38">CHEMBL38</a>	FAB classification M3 Acute promyelocytic leukemia	SFTPA1; RXRA; EHMT2; TGFBR3; RXRB; TBP; ALDH1A2; RARA; SMARCA4; SMAD2; NR2C1; HIF1A; P2RY2; AMH; SHH; NOS1; CDKN1B; PRL; THBS1; NPM1; TGFB1; TSPYL2; RARG; RET; HES1; MYOD1; BIRC5; IL1R1; BCKDHB; CEACAM1; RAB40B; NRIP1; CXCL8; RB1; XIAP; RARB; RXRG; SPP1; FLT3; MYCN; ERVK2; KLK3; BCHEL1; BCL2L2; BAX; WT1; TG; HOXB1; APOA1; ITGB2; NFE2L2; FAS; MDK; FUS; SLC2A1; PTPRZ1; CD55; TP73; VDR; HAS3; NR2C2; PTCH1; BHLHE40; RPE65; TPO; LIF; DUSP6; BCHE; BCL2; OCLN; CYP2C9; ALPL; KAT2A; HOXD1; IL10; USP1; RARRES1; NR2E1; CYP3A5; GLI1; PML; CALR; MAPK8; MST1; IFNG; EGR2; HSPA8; NR4A1; APOE; BCHEL3; ADH1C	2024-07-25	
Trifluridine, Tipiracil	Y	Y	N		N	1980	Y	<a href="https://go.drugbank.com/drugs/DB00432">DB00432</a>	L01BC59; S01AD02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1129">CHEMBL1129</a>	Metastatic Colorectal Cancer (MCRC)	ERBB2; SLC29A1; TP53	2024-02-07	
Triptorelin	N	Y	Y		N	2000	N	<a href="https://go.drugbank.com/drugs/DB06825">DB06825</a>	L02AE04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201334">CHEMBL1201334</a>	Advanced Prostate Cancer	GNRHR; STS	2024-07-24	
Trofosfamide	N	N	Y		N			<a href="https://go.drugbank.com/drugs/DB12902">DB12902</a>	L01AA07	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL462019">CHEMBL462019</a>	Non-Hodgkin&#39;s lymphoma	CYP2B6	2024-02-07	
Tucatinib	Y	Y	N		N	2020	N	<a href="https://go.drugbank.com/drugs/DB11652">DB11652</a>	L01EH03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989868">CHEMBL3989868</a>	Breast Cancer; Unresectable Breast Cancer	ERBB2; NRAS; HRAS; EN1; EGFR; DXO; KRAS; ERBB4	2024-07-24	
Umbralisib	N	Y	N		N	2021	N	<a href="https://go.drugbank.com/drugs/DB14989">DB14989</a>	L01EX25	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3948730">CHEMBL3948730</a>	B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL)	PIK3CD; PIK3CG; ELF2; F7	2024-07-24	
Valrubicin	N	Y	N		N	1998	Y	<a href="https://go.drugbank.com/drugs/DB00385">DB00385</a>	L01DB09	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1096885">CHEMBL1096885</a>	In situ BCG-refractory Bladder carcinoma	TOP2A; AR	2024-02-07	
Vandetanib	Y	Y	N		N	2011	N	<a href="https://go.drugbank.com/drugs/DB05294">DB05294</a>	L01EX04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL24828">CHEMBL24828</a>	Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer	KDR; RET; PTEN; EGFR; LRRK2; ERBB4; FLT4; FLT1; ALK; FYN; MAP4K5; PDGFRB; GMNN; LCK; KRAS; EPHA1; SRC; EPHB1; EPHA3; TYRO3; AURKB; EPHB4; EPHB3; EPHA10; MAP2K2; IDH1; DRD2; BTK; ABL1; MAP2K1; PTK6; EPHB6; EPHA2; HTT; AXL; FGFR1; CYP3A4; APC; ROCK2; EPHB2; EPHA5; PTK2B; EPHA4; YES1; ERBB2; PDGFRA; DXO; TEK; MTOR; ERBB3; MAPK14; MAP4K4; ATM; LTK; EPHA6; EPHA7; ACVR1; EPHA8	2024-07-24	
Vemurafenib	Y	Y	N		N	2011	N	<a href="https://go.drugbank.com/drugs/DB08881">DB08881</a>	L01EC01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1229517">CHEMBL1229517</a>	Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer	CDKN2A; NRAS; PIK3CA; MITF; PTEN; RB1; MET; PIK3R2; RAC1; BRAF; PREX2; HRAS; NF1; CYP3A4; TET2; MAP2K1; ATXN1L; EFNA2; TP53; KEAP1; CBL; CIC; FGFR2; KRAS; ABCB1; STAG3; YES1; FAH; MAP2K2; CYP1A2; CYP3A; TF; STAG2; SOX10; AKT1; AKT3	2024-07-24	
Venetoclax	Y	Y	N		N	2016	N	<a href="https://go.drugbank.com/drugs/DB11581">DB11581</a>	L01XX52	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3137309">CHEMBL3137309</a>	Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma	IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1	2024-07-24	
Vinblastine	N	Y	Y		Y	1965	Y	<a href="https://go.drugbank.com/drugs/DB00570">DB00570</a>	L01CA01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL159">CHEMBL159</a>	Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi&#39;s sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer	TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1	2024-07-24	
Vincristine	N	Y	Y		Y	1965	Y	<a href="https://go.drugbank.com/drugs/DB00541">DB00541</a>	L01CA02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL90555">CHEMBL90555</a>	Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing&#39;s Sarcoma; Hepatoblastomas; Kaposi&#39;s sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin&#39;s Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms&#39; tumor; Advanced Thymoma	NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA	2024-07-24	
Vincristine Liposome	N	Y	N		N	2012	Y	<a href="https://go.drugbank.com/drugs/DB00541">DB00541</a>	L01CA02	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL501867">CHEMBL501867</a>	Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing&#39;s Sarcoma; Hepatoblastomas; Kaposi&#39;s sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin&#39;s Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms&#39; tumor; Advanced Thymoma	TUBB6; TUBB3; TUBA3C; ALK; TUBB4A; GMNN; TUBB8; TUBB4B; TUBB2B; TUBA1A; TUBB1; TUBB; TUBA4A; HIF1A; TUBA3E; TUBA1C; NR0B1; TUBA1B; TUBB2A	2024-07-24	
Vindesine	N	N	Y		N	1979	N	<a href="https://go.drugbank.com/drugs/DB00309">DB00309</a>	L01CA03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL238071">CHEMBL238071</a>	Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant	TUBB; ABCB1; TUBB1; CYP3A4	2024-07-24	
Vinflunine	Y	N	N		N	2009	N	<a href="https://go.drugbank.com/drugs/DB11641">DB11641</a>	L01CA05	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2110725">CHEMBL2110725</a>	Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract	TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B	2024-07-24	
Vinorelbine	N	Y	Y		Y	1994	Y	<a href="https://go.drugbank.com/drugs/DB00361">DB00361</a>	L01CA04	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL553025">CHEMBL553025</a>	Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer	TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8	2024-07-24	
Vismodegib	Y	Y	N		N	2012	N	<a href="https://go.drugbank.com/drugs/DB08828">DB08828</a>	L01XJ01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL473417">CHEMBL473417</a>	Locally Advanced Basal Cell Carcinoma; Metastatic Basal cell carcinoma	SMO; PTCH1; SHH; ALOX12	2024-07-24	
Vorinostat	N	Y	N		N	2006	N	<a href="https://go.drugbank.com/drugs/DB02546">DB02546</a>	L01XH01	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL98">CHEMBL98</a>	Persistent Cutaneous T-Cell Lymphoma; Progressive Cutaneous T-cell lymphoma; Recurrent Cutaneous T-cell lymphoma	TUBA1C; TUBA3D; IDH1; PAX8; TUBB4A; TUBB4B; GAS1; GAPDHP1; HDAC9; TUBB2A; TUBB8; HDAC6; BRAF; NR0B1; HDAC7; HDAC2; GART; HDAC8; GAPDHL17; HDAC11; HDAC4; GAS2; HDAC5; BIRC5; HDAC1; CFTR; TUBA3C; HDAC3; GDF2; GARS1; MYC; TP53; TUBA1A; TUBA3E; CHD4; MSTN; TUBB2B; UGT2B17; TUBA1B; TUBB6; TUBB1; LRRC32; BAP1; GMNN; TUBB3; ERBB2; FBXW7; NFE2L2; ACE; GNA11; HDAC10; TUBB; PTEN; RB1; TUBA4A	2024-07-24	
Zanubrutinib	Y	Y	N		N	2019	N	<a href="https://go.drugbank.com/drugs/DB15035">DB15035</a>	L01EL03	<a href="https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3936761">CHEMBL3936761</a>	Mantle Cell Lymphoma (MCL)	TP53; BTK; EFNB2; MYD88	2024-07-24	

